

09/869135

SPECIFICATION 003 Rec'd PGT/PTC 25 JUN 2001

IMIDAZOLE COMPOUNDS AND MEDICINAL USE THEREOF**Technical Field**

The present invention relates to novel imidazole compounds.
5 More particularly, the present invention relates to novel
imidazole compounds and salts thereof having hypoglycemic
activity or PDE-V inhibitory activity. The present invention also
relates to a method for producing the above-mentioned imidazole
compounds and salts thereof. Moreover, the present invention
10 relates to pharmaceutical compositions comprising the above-
mentioned imidazole compound or a salt thereof as an active
ingredient.

Disclosure of the Invention

The present invention aims at providing novel imidazole
15 compounds, pharmaceutically acceptable salts thereof and
pharmaceutical preparations comprising the above-mentioned
imidazole compound or a pharmaceutically acceptable salt thereof
as an active ingredient, which are used as an agent for the
prophylaxis and/or treatment of impaired glucose tolerance
20 disorder, diabetes (e.g., type II diabetes), gestational diabetes,
diabetic complications (e.g., diabetic gangrene, diabetic
arthropathy, diabetic osteopenia, diabetic glomerulosclerosis,
diabetic nephropathy, diabetic dermatopathy, diabetic neuropathy,
diabetic cataract, diabetic retinopathy and the like), insulin
25 resistance syndrome (e.g., insulin receptor abnormality, Rabson-
Mendenhall syndrome, leprechaunism, Kobberling-Dunnigan syndrome,
Seip syndrome, Lawrence syndrome, Cushing syndrome, acromegaly and
the like), polycystic ovary syndrome, hyperlipidemia,
atherosclerosis, cardiovascular diseases (e.g., stenocardia,
30 cardiac failure and the like), hyperglycemia (e.g., those
characterized by abnormal saccharometabolism such as eating
disorders), pancreatitis, osteoporosis, hyperuricemia,
hypertension, inflammatory bowel diseases, and skin disorders
related to an anomaly of differentiation of epidermic cells; and,
35 which, based on the cGMP-PDE (particularly PDE-V) inhibitory
action, smooth muscle relaxing action, bronchodilating action,
vasodilating action, smooth muscle cell inhibitory action, allergy
suppressing action and the like, are used as an agent for the
prophylaxis and/or treatment of angina pectoris, hypertension,
40 pulmonary hypertension, congestive heart failure, glomerulopathy

(e.g., diabetic glomerulosclerosis), tubulointerstitial disorders (e.g., kidney diseases induced by FK506, cyclosporin and the like), renal failure, atherosclerosis, angiostenosis (e.g., after percutaneous arterioplasty), peripheral vascular diseases, cerebral apoplexy, chronic reversible obstructive impairment (e.g., bronchitis, asthma inclusive of chronic asthma and allergic asthma), autoimmune diseases, allergic rhinitis, urticaria, glaucoma, diseases characterized by impaired intestinal motility (e.g., irritable bowel syndrome), impotence (e.g., organic impotence, psychic impotence and the like), nephritis, cancer cachexia, restenosis after PTCA, cachexia (e.g., progressive weight loss due to lipolysis, myolysis, anemia, edema, anorexia and the like in chronic diseases such as cancer, tuberculosis, endocrine diseases and AIDS), and the like.

[illegible]

R¹ is an aryl or heterocyclic group substituted by a substituent selected from the group consisting of (1) aryl, (2) heterocyclic group, (3) halogen, (4) halo(lower)alkyl, (5) lower alkylthio, (6) nitro, (7) lower alkenyl optionally substituted by aryl, (8) lower alkynyl optionally substituted by aryl, (9) lower alkoxy optionally substituted by cyclo(lower)alkyl or aryl, (10) aryloxy and (11) amino optionally substituted by protected carboxy or lower alkyl;

R^3 is a hydrogen, halogen, lower alkyl or nitro;

2

optionally substituted by halogen;


A is a lower alkylene; and

L is a single bond, lower alkenylene or lower alkylene optionally substituted by aryl or heterocyclic group, or $-X-CH_2-$ wherein X is $-O-$, NR^5 wherein R^5 is hydrogen or lower alkyl, or $-S-$.

Preferred salts of the objective compound (I) are conventional salts that are non-toxic and acceptable for use as pharmaceuticals. Examples thereof include salts with alkali metal
10 such as sodium and potassium, salts with alkaline earth metal such as calcium and magnesium, salts with inorganic base such as ammonium salt, salts with organic amine such as triethylamine, pyridine, picoline, ethanolamine and triethanolamine, salts with inorganic acid such as hydrochloric acid, hydrobromic acid,
15 sulfuric acid and phosphoric acid, salts with organic carboxylic acid such as formic acid, acetic acid, trifluoroacetic acid, maleic acid and tartaric acid, addition salts with sulfonic acid such as methanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid, and salts or addition salts with base such
20 as basic or acidic amino acid such as arginine, aspartic acid and glutamic acid.

The objective compound (I) and a salt thereof of the present invention can be produced by the method shown by the following reaction formulas.

25 **Production Method 1:**



or reactive derivative at or a salt thereof
carboxyl group thereof,
or their salts

"Cyclo(lower)alkyl" is cycloalkyl having 3 to 10, preferably 3 to 7, carbon atoms. Preferable examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, with more preference given to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

Examples of preferable "lower alkylene" include methylene, ethylene, propylene, butylene, pentylene, hexylene and the like, with particular preference given to alkylene having up to 4 carbon atoms. Of these, particularly preferred is methylene.

10 Examples of preferable "lower alkynyl" include linear or branched alkynyl, such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 2-methyl-3-butynyl, 1,1-dimethyl-2-butynyl, 1-hexynyl, 5-hexynyl and the like.

15 Of these, particularly preferred is alkynyl having 2 to 6 carbon atoms, which is more preferably ethynyl.

Examples of preferable "lower alkenylene" include linear or branched alkenylene, such as ethenylene, 1-propenylene, 2-propenylene, 1-butenylene, 2-butenylene, 3-butenylene, 1-pentenylene, 2-pentenylene, 3-pentenylene, 4-pentenylene, 1-hexenylene, 2-hexenylene, 3-hexenylene, 4-hexenylene, 5-hexenylene, methyl ethenylene, ethyl ethenylene, 1-pentyl ethenylene and the like.

Of these, particularly preferred is alkenylene having up to 25 4 carbon atoms, more preferably ethenylene.

"Lower alkoxy" is linear or branched alkyloxy having up to 6 carbon atoms. Preferable examples thereof include methoxy, ethoxy, 1-propyloxy, i-propyloxy, 1-butyloxy, i-butyloxy, sec-butyloxy, t-butyloxy, 1-pentyloxy, i-pentyloxy, sec-pentyloxy, t-pentyloxy, 2-methylbutoxy, 1-hexyloxy, i-hexyloxy, t-hexyloxy, sec-hexyloxy, 2-methylpentyloxy, 3-methylpentyloxy, 1-ethylbutyloxy, 2-ethylbutyloxy, 1,1-dimethylbutyloxy, 2,2-dimethylbutyloxy, 3,3-dimethylbutyloxy, 1-ethyl-1-methylpropyloxy, and the like.

More preferred is alkoxy having up to 5 carbon atoms, such
35 as methoxy, ethoxy, 1-propyloxy, i-propyloxy, 1-butyloxy, i-
butyloxy, sec-butyloxy, t-butyloxy, 1-pentyloxy and the like.

"Halogen" is exemplified by fluorine atom, chlorine atom, bromine atom and iodine atom.

"Halo(lower)alkyl" is a linear or branched alkyl having up to 6 carbon atoms, which is substituted by fluorine atom, chlorine

heteromonocyclic group having 1 or 2 sulfur atoms, such as thienyl, dihydrodithinyl, dihydrodithionyl and the like.

(8) Saturated 3 to 8-membered (more preferably 5- or 6-membered) heteromonocyclic group having 1 or 2 oxygen atoms, such as tetrahydrofuryl, tetrahydropyranyl and the like.

(9) Unsaturated 3 to 8-membered (more preferably 5- or 6-membered) heteromonocyclic group having one oxygen atom, such as furyl and the like.

(10) Spiroheterocyclic group having 1 or 2 oxygen atoms, such as
10 dioxaspirodecanyl (e.g., 1,5-dioxaspiro[5,5]undecanyl) and the
like.

(11) Unsaturated 3 to 8-membered (more preferably 5- or 6-membered) heteromonocyclic group having one oxygen atom and 1 or 2 sulfur atoms, such as dihydroxathinyl.

15 Examples of heteropolycyclic group include the following.

(12) Saturated or unsaturated 7 to 12-membered (more preferably 8 to 10-membered) heteropolycyclic (more preferably heterodicyclic) group having 1 to 4 nitrogen atoms.

Specific examples thereof include benzimidazolyl, indolyl,
20 2,3-dihydrobenzimidazolyl, pyrazolopyrimidinyl (e.g.,
pyrazolo[1,5-a]pyrimidinyl), tetrahydropyrazolopyrimidinyl (e.g.,
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidinyl), imidazopyrazolyl
(e.g., 4H-imidazo[1,2-b]pyrazolyl), dihydroimidazopyrazolyl (e.g.,
2,3-dihydroimidazo[1,2-b]pyrazolyl), imidazopyridyl (e.g.,
25 imidazo[1,5-a] (or [1,2-a] or [3,4-a])pyridyl, 1H (or 3H)-
imidazo[4,5-b] (or [4,5-c])pyridyl), pyrrolopyridyl (e.g., 1H-
pyrrolo[3,2-b]pyridyl), pyrazolopyridyl (e.g., pyrazolo[1,5-a] (or
[2,3-a]pyridyl, 1H (or 2H)-pyrazolo[4,3-b]pyridyl), benzopyrazolyl
(e.g., 1H (or 2H)-benzo[c]pyrazolyl), dihydrobenzimidazolyl,
30 benzotriazolyl (e.g., benzo[d][1H-1,2,3]triazolyl), indolidinyl,
isoindolyl (e.g., 1H-isoindolyl), indazolyl (e.g., 1H (or 2H or
3H)-indazolyl), indolinyl, isoindolinyl, purinyl, quinolidinyl
(e.g., 4H-quinolidinyl), isoquinolyl, quinolyl, phthaladinyl,
naphthalidinyl (e.g., 1,8-naphthalidinyl), quinoxalinyl,
35 dihydroquinoxalinyl (e.g., 1,2-dihydroquinoxalinyl),
tetrahydroquinoxalinyl (e.g., 1,2,3,4-tetrahydroquinoxalinyl),
quinazolinyl, dihydroquinazolinyl (e.g., 1,4 (or 3,4)-
dihydroquinazolinyl), tetrahydroquinazolinyl (e.g., 1,2,3,4-
tetrahydroquinazolinyl), cinnolinyl, pteridinyl,
40 pyrazinopyridazinyl (e.g., pyrazino[2,3-d]pyridazinyl),

imidazotriazinyl (e.g., imidazo[1,2-b][1,2,4]triazinyl),
imidazopyrazinyl (e.g., 1H-imidazo[4,5-b]pyrazinyl),
imidazopyrimidine (e.g., 3H-purine and imidazo[1,5-a] (or [3,4-
a])pyrimidine), imidazopyridazinyl (e.g., imidazo[2,3-b] (or [3,4-
5 b])pyridazinyl), 1H-1-(or 2)pyrimidinyl and the like.

(13) Saturated or unsaturated 7 to 12-membered (more preferably 8 to 10-membered) heteropolycyclic (more preferably heterodicyclic) group having 1 to 3 oxygen atoms.

Specific examples thereof include benzofuranyl (e.g.,
10 benzo[b](or [c])furanyl), isobenzofuranyl, furopyridyl, chromenyl
(e.g., 2H-chromenyl), chromanyl, isochromanyl, benzoxepinyl (e.g.,
3-benzoxepinyl), cyclopentapyranyl (e.g., cyclopenta[b]pyranyl),
furopyranyl (e.g., 2H-furo[3,2-b]pyranyl, and the like.

(14) Saturated or unsaturated 7 to 12-membered (more preferably 8 to 10-membered) heteropolycyclic (more preferably heterodicyclic) group having 1 to 3 sulfur atoms.

Specific examples thereof include benzothiophenyl (e.g., benzo[b]thiophenyl), dihydrodithianaphthalenyl (e.g., 4H-1,3-dithianaphthalenyl), dithianaphthalenyl (e.g., 1,4-dithianaphthalenyl) and the like.

(15) Saturated or unsaturated 7 to 12-membered (more preferably 8 to 10-membered) heteropolycyclic (more preferably heterodicyclic) group having 1 to 3 nitrogen atoms and 1 or 2 oxygen atoms.

Specific examples thereof include dioxoloimidazolyl (e.g.,
25 4H-1,3-dioxolo[4,5-d]imidazolyl, benzoxazinyl (e.g., 4H-3,1-
benzoxazinyl), pyridooxazinyl (e.g., 5H-pyrido[2,3-d]oxazinyl),
pyrazolooxazolyl (e.g., 1H-pyrazolo[4,3-d]oxazolyl), furopyridyl,
and the like.

(16) Saturated or unsaturated 7 to 12-membered (more preferably 8 to 10-membered) heteropolycyclic (more preferably heterodicyclic) group having 1 to 3 nitrogen atoms and 1 or 2 sulfur atoms.

Specific examples thereof include thienoimidazolyl (e.g., thieno[2,3-d]imidazolyl), thienopyridyl, dithiadiazaindanyl (e.g., 2,3-dithia-1,5-diazaindanyl) and the like.

35 (17) Saturated or unsaturated 7 to 12-membered (more preferably 8 to 10-membered) heteropolycyclic (more preferably heterodicyclic) group having 1 to 3 oxygen atoms and 1 or 2 sulfur atoms.

Specific examples thereof include thienofuranyl (e.g., thieno[2,3-b]furanyl) and the like.

40 (18) Saturated or unsaturated 7 to 12-membered (more preferably 8

to 10-membered) heteropolycyclic (more preferably heterodicyclic) group having 1 nitrogen atom, 1 oxygen atom and 1 sulfur atom.

Specific examples thereof include oxathiolopyrrolyl (e.g., 4H[1,3]-oxathio[5,4-b]pyrrolyl) and the like.

- 5 (19) Saturated or unsaturated 7 to 12-membered (more preferably 8 to 10-membered) heteropolycyclic (more preferably heterodicyclic) group having 1 or 2 selenium atoms.

Preferable examples thereof include benzoselenophenyl (e.g., benzo[b](or [c])selenophenyl) and the like.

- 10 (20) Saturated or unsaturated 7 to 12-membered (more preferably 8 to 10-membered) heteropolycyclic (more preferably heterodicyclic) group having 1 or 2 selenium atoms and 1 to 3 nitrogen atoms.

Specific examples thereof include selenopyridyl (e.g., seleno[3,2-b]pyridyl) and the like.

- 15 The preferable "aryl moiety" of "aryloxy" is the above-mentioned "aryl moiety", which is more preferably phenyl.

"Protected carboxy" is preferably esterified carboxy.

Examples of preferable ester moiety of the esterified carboxy include:

- 20 lower alkyl esters, such as methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, t-butyl ester, pentyl ester and hexyl ester, optionally having at least one appropriate substituent, which is exemplified by lower alkanoyloxy(lower)alkyl ester (e.g., acetoxymethyl ester,
- 25 propionyloxymethyl ester, butyryloxymethyl ester, valeryloxymethyl ester, pivaloyloxymethyl ester, hexanoyloxymethyl ester, 1 (or 2)-acetoxylethyl ester, 1 (or 2 or 3)-acetoxypentyl ester, 1 (or 2, 3 or 4)-acetoxypentyl ester, 1 (or 2)-propionyloxyethyl ester, 1 (or 2 or 3)-propionyloxypropyl ester, 1 (or 2)-butyryloxyethyl ester,
- 30 1 (or 2)-isobutyryloxyethyl ester, 1 (or 2)-pivaloyloxyethyl ester, 1 (or 2)-hexanoyloxyethyl ester, isobutyryloxymethyl ester, 2-ethylbutyryloxymethyl ester, 3,3-dimethylbutyryloxymethyl ester, 1 (or 2)-pentanoyloxyethyl ester), lower alkanesulfonyl(lower)alkyl ester (e.g., 2-mesylethyl ester), mono- (or di- or tri)-
- 35 halo(lower)alkyl ester (e.g., 2-iodoethyl ester and 2,2,2-trichloroethyl ester), lower alkoxycarbonyloxy(lower)alkyl ester (e.g., methoxycarbonyloxymethyl ester, ethoxycarbonyloxymethyl ester, 2-methoxycarbonyloxyethyl ester, 1-ethoxycarbonyloxyethyl ester and 1-isopropoxycarbonyloxyethyl ester),
- 40 phthalidilidene(lower)alkyl ester and (5-lower alkyl-2-oxo-1,3-

L is ethenylene
and a salt thereof.

Of the above-mentioned compounds (IA), a compound wherein R⁴ is aryl or lower alkenyl optionally substituted by aryl, R⁶ is bromine, lower alkenyl substituted by aryl, lower alkynyl substituted by aryl or lower alkoxy optionally substituted by cyclo(lower)alkyl and a salt thereof are particularly preferable.

Of the above-mentioned compounds (I), a compound wherein R¹ is heterocyclic group substituted by a substituent selected from the group consisting of (1) aryl, (2) heterocyclic group, (3) halogen, (4) halo(lower)alkyl, (5) lower alkylthio, (6) nitro, (7) lower alkenyl optionally substituted by aryl, (8) lower alkynyl optionally substituted by aryl, (9) lower alkoxy optionally substituted by cyclo(lower)alkyl or aryl, (10) aryloxy and (11) amino optionally substituted by protected carboxy or lower alkyl, and a salt thereof are more preferable.

Of these, particularly preferable groups are specifically exemplified by the following.

R¹ : 2-chloro-4-(2-furyl)phenyl, 2-chloro-4-(2-thienyl)phenyl, 2-chloro-4-(phenylethynyl)phenyl, 4-bromo-2-chlorophenyl, 3-chloro-4-biphenyl, 2-chloro-4-(1-propoxy)phenyl, 2-chloro-4-(1-pentyloxy)phenyl, 2-chloro-4-((cyclopentyl)methyloxy)phenyl, 2-chloro-4-((cyclohexyl)methyloxy)phenyl, 4-benzyloxy-2-chlorophenyl, 2-chloro-4-(methylthio)phenyl, 2-chloro-4-(trifluoromethyl)phenyl, 2-chloro-4-(phenoxyethyl)phenyl, 2-chloro-4-nitrophenyl, 2-chloro-4-((E)-2-phenylethenyl)phenyl, 1-bromo-2-naphthyl,

R² : methyl,

R^3 : chlorine,

R⁴: p-tolyl, (E)-2-phenylethenyl, pentyl, phenyl, 5-chloro-2-thienyl, 5-bromo-2-thienyl,

R⁶: 2-furyl, 2-thienyl, phenylethynyl, bromine, phenyl, 1-propoxy, 1-pentyloxy, (cyclopentyl)methyloxy, (cyclohexyl)methyloxy, benzyloxy, methylthio, trifluoromethyl, phenoxyethyl, nitro, (E)-2-phenylethenyl,

A: methylene,

L: ethenylene.

Preferable specific compounds as the objective compound (I) are exemplified by the following.

- (1) (E)-3-(4-chloro-1-(2-chloro-4-(2-furyl)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- 5 (2) (2E)-3-(4-chloro-1-(2-chloro-4-(2-furyl)benzyl)-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (3) (E)-3-(4-chloro-1-(2-chloro-4-(2-thienyl)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- 10 (4) (2E)-3-(4-chloro-1-(2-chloro-4-(2-thienyl)benzyl)-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (5) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- 15 (6) (2E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (7) (E)-3-(1-(4-bromo-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- 20 (8) (E)-3-(1-(4-bromo-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (9) (E)-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-N-(1-pentanesulfonyl)-2-propenamide,
- (10) (E)-N-benzenesulfonyl-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-2-propenamide,
- 25 (11) (E)-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- (12) (E)-3-(4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- 30 (13) (E)-3-(4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl)-N-((5-chloro-2-thienyl)sulfonyl)-2-propenamide,
- (14) (E)-N-((5-bromo-2-thienyl)sulfonyl)-3-(4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl)-2-propenamide,
- (15) (E)-3-((4-chloro-1-(2-chloro-4-(1-propoxy)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- 35 (16) (E)-3-(4-chloro-1-(2-chloro-4-(1-propoxy)benzyl)-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (17) (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- 40

- (18) (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (19) (E)-3-(4-chloro-1-(2-chloro-4-((cyclopentyl)methyloxy)-benzyl)-2-methylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide,
- 5 (20) (E)-3-(4-chloro-1-(2-chloro-4-((cyclopentyl)methyloxy)-benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- (21) (2E)-3-(4-chloro-1-(2-chloro-4-((cyclopentyl)methyloxy)-benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- 10 (22) (E)-3-(4-chloro-1-(2-chloro-4-((cyclohexyl)methyloxy)-benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- (23) (2E)-3-(4-chloro-1-(2-chloro-4-((cyclohexyl)methyloxy)-benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- 15 (24) (E)-3-(1-(4-benzyloxy-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- 20 (25) (E)-3-(1-(4-benzyloxy-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (26) (E)-3-(4-chloro-1-(2-chloro-4-(methylthio)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- 25 (27) (E)-3-(4-chloro-1-(2-chloro-4-(methylthio)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (28) (E)-3-(4-chloro-1-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- 30 (29) (E)-3-(4-chloro-1-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (30) (E)-3-(4-chloro-1-(2-chloro-4-(phenoxy)methyl)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- 35 (31) (E)-3-(4-chloro-1-(2-chloro-4-(phenoxy)methyl)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (32) (E)-3-(4-chloro-1-(2-chloro-4-nitrobenzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- 40 (33) (E)-3-(4-chloro-1-(2-chloro-4-nitrobenzyl)-2-methylimidazol-

5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
(34) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
(35) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
(36) (E)-3-(1-(1-bromo-2-naphthyl)-4-chloro-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
(37) (E)-3-(1-(1-bromo-2-naphthyl)-4-chloro-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
(38) (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide,
(39) (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-N-((E)-1-penten-1-ylsulfonyl)-2-propenamide,
(40) (E)-N-(1-butanesulfonyl)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-propenamide,
(41) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide,
(42) (E)-(3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-N-((E)-1-penten-1-ylsulfonyl)-2-propenamide,
(43) (E)-N-(1-butanesulfonyl)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-2-propenamide,
(44) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide,
(45) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-((E)-1-penten-1-ylsulfonyl)-2-propenamide,
(46) (E)-N-(1-butanesulfonyl)-3-(4-chloro-1-(2-chloro-4-(2-phenylethynyl)benzyl)-2-methylimidazol-5-yl)-2-propenamide,
(47) (E)-3-(4-chloro-1-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenylsulfonyl)-2-propenamide,
(48) (E)-3-(4-chloro-1-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
(49) (E)-3-(1-(4-(tert-butoxycarbonylamino)-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide,
(50) (E)-3-(1-(4-(tert-butoxycarbonylamino)-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-((E)-1-penten-1-ylsulfonyl)-2-propenamide,
(51) (E)-3-(1-(4-(tert-butoxycarbonylamino)-2-chlorobenzyl)-4-

- chloro-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide,
- (52) (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-ethylimidazol-5-yl)-N-((E)-2-phenylethenesulfonyl)-2-propenamide,
- 5 (53) (E)-3-(1-(4-bromo-2-chlorobenzyl)-4-chloro-2-ethylimidazol-5-yl)-N-((E)-2-phenylethenesulfonyl)-2-propenamide,
- (54) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-N-((E)-2-phenylethenesulfonyl)-2-propenamide,
- (55) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide,
- 10 (56) (E)-N-(1-butanesulfonyl)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-2-propenamide,
- (57) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide,
- 15 (58) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-N-((E)-1-penten-1-ylsulfonyl)-2-propenamide,
- (59) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-ethylimidazol-5-yl)-N-((E)-2-phenylethenesulfonyl)-2-propenamide,
- (60) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-ethylimidazol-5-yl)-N-(4-methylbenzenesulfonyl)-2-propenamide,
- 20 (61) (E)-N-(1-butanesulfonyl)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-ethylimidazol-5-yl)-2-propenamide,
- (62) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-ethylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide,
- 25 (63) (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-ethylimidazol-5-yl)-N-((E)-1-penten-1-ylsulfonyl)-2-propenamide,
- (64) (E)-3-(1-(4-bromo-2-chlorobenzyl)-2,4-dimethylimidazol-5-yl)-N-((E)-2-phenylethenesulfonyl)-2-propenamide,
- (65) (E)-3-(4-bromo-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenesulfonyl)-2-propenamide,
- 30 (66) (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-4-ethyl-2-methylimidazol-5-yl)-N-((E)-2-phenylethenesulfonyl)-2-propenamide,
- (67) (E)-2-benzyl-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenesulfonyl)-2-propenamide,
- 35 (68) (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-(1-pentyl)-N-((E)-2-phenylethenesulfonyl)-2-propenamide,
- (69) (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-(3-pyridyl)methyl-N-((E)-2-phenylethenesulfonyl)-2-propenamide,
- 40 (70) (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-

yl)-2-methyl-N-((E)-2-phenylethanesulfonyl)-2-propenamide,
(71) (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-methyl-N-((E)-2-phenylethanesulfonyl)-2-propenamide,
5 (72) 4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-5-((E)-2-phenylethanesulfonylcarbamoyl)-1H-imidazole,
(73) (4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-1H-imidazol-5-yl)methyl N-(4-methylbenzenesulfonyl) carbamate,
(74) 4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-5-((3-(4-methylbenzenesulfonyl)ureido)methyl)-2-methyl-1H-imidazole,
10 (75) 4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-5-((3-(4-methylbenzenesulfonyl)-1-methylureido)methyl)-2-methyl-1H-imidazole, and
(76) (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-N-((E)-1-penten-1-yl)-1-ylsulfonyl)-2-propenamide and sodium salt thereof.

The production methods of the objective compound (I) are explained in detail in the following.

Production Method 1:

20 The objective compound (I) and a salt thereof can be produced by reacting compound (II) or reactive derivative at carboxy thereof or a salt thereof with compound (III) or a salt thereof.

Examples of preferable salt of compound (II), reactive
25 derivative at carboxy group thereof and compound (III) include
those shown with regard to compound (I).

Preferable reactive derivative at carboxy of compound (II) is acid halide, acid anhydride inclusive of intramolecular acid anhydride, intermolecular acid anhydride and mixed acid anhydride, 30 active amide, active ester and the like. Preferable examples thereof include acid chloride, acid azide, mixed acid anhydride with acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid and halogenated phosphoric acid), 35 dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid (e.g., methanesulfonic acid), aliphatic carboxylic acid (e.g., acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid and trichloroacetic acid), 40 aromatic carboxylic acid (e.g., benzoic acid) and the like;

symmetric acid anhydride; active amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; active ester (e.g., cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl [(CH₃)₂N⁺=CH-] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenylthio ester, p-nitrophenylthio ester, p-cresylthio ester, carboxymethylthio ester, pyranyl ester, pyridyl ester, piperidyl ester and 8-quinolylthio ester); esters with N-hydroxy compound (e.g., N,N-dimethylhydroxylamine, 1-hydroxy-2-1H-pyridone, N-hydroxysuccinimide and 1-hydroxy-1H-benzotriazole); and the like. These reactive derivatives can be appropriately selected according to the kind of compound (II) to be used.

15 The reaction generally proceeds in a conventional solvent
such as water, alcohol (e.g., methanol and ethanol), acetone,
dioxane, acetonitrile, chloroform, methylene chloride, ethylene
chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide
and pyridine, or a mixture thereof, or in any other solvent which
20 does not adversely affect the reaction. These conventional
solvents may be used alone or in combination.

When compound (II) is used in the form of a free acid or a salt thereof in this reaction, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide, N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, N,N'-carbonylbis(2-methylimidazole), pentamethyleneketene-N-cyclohexylimine, diphenylketene-N-cyclohexylimine, ethoxyacetylene, 1-alkoxy-1-chloroethylene, trialkyl phosphite, ethyl polyphosphate, isopropyl polyphosphate, phosphorous oxychloride (phosphoryl chloride), phosphorus trichloride, diphenylphosphoryl azide, diphenyl chlorophosphate, diphenylphosphinic chloride, thionyl chloride, oxaryl chloride, lower alkyl haloformate (e.g., ethyl chloroformate and isopropyl chloroformate), triphenylphosphine, 2-ethyl-7-hydroxybenz-isoxazorium salt, intramolecular salt of 2-ethyl-5-(m-sulfohenyl)isoxazorium hydroxide, 1-(p-chlorobenzene-sulfonyloxy)-6-chloro-1H-benzotriazole, so-called Vilsmeier

reagent(prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorous oxychloride, and so on), and the like.

The reaction can be carried out in the presence of an
5 inorganic or organic base such as alkali metal bicarbonate,
tri(lower)alkylamine, pyridine, 4-dimethylaminopyridine, N-
(lower)alkylmorpholine, N,N-di(lower)alkylaniline (e.g., N,N-
dimethylaniline), N,N-di(lower)alkylbenzylamine and the like.

The reaction temperature is not particularly limited, and
10 the reaction is generally carried out under cooling to heating.

The aforementioned compounds can be converted to preferable salts as necessary by a conventional method. All of them can be purified as necessary according to a conventional method for purifying an organic compound (i.e., recrystallization, column chromatography, thin layer chromatography, high performance liquid chromatography and the like). The compound can be identified by NMR spectrum analysis, mass spectrum analysis, IR spectrum analysis, elemental analysis, melting point measurement and the like.

20 The compound of the present invention may have one or more chiral centers and, therefore, may be present as enantiomers and diastereomers. Some compounds having alkenyl may be present as a cis or trans isomer. In any case, the present invention encompasses such mixtures and respective isomers.

25 The inventive compound and a salt thereof may be in the form of a solvate, which is also encompassed in the present invention. The solvate is preferably exemplified by hydrate and ethanol solvate.

The pharmaceutical data of compound (I) are shown in the
30 following to demonstrate the utility of the objective compound (I).

Experimental Example 1

(blood sugar level depressing activity in db/db mice)

Test compound

compound A:

35 (E)-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-N-((4-methylbenzene)sulfonyl)-2-propenamide (compound of Example 11)

Animal

Female C57BL/KsJ-dbm db+/db+, C57BL/KsJ-dbm +m/+m (Jackson
40 Laboratory) mice (5 weeks old) were purchased and subjected to

administered with the test drug was determined. The results are shown in Table 1.

Table 1

Test compound	Dose (mg/kg)	Blood sugar decrease (%)
Compound A	3.2	63

5 The compound (I) of the present invention can be used for therapeutic purposes in the form of a pharmaceutical preparation. This pharmaceutical preparation contains any one of the compounds (I) as an active ingredient in admixture with a pharmaceutically acceptable organic or inorganic excipient which is a solid, semi-
10 solid or liquid and which is suitable for oral, parenteral or external (local) administration. Examples of the pharmaceutical preparation include capsules, tablets, sugar coating tablets, granules, suppositories, liquid, lotion, suspension, emulsion, ointment, gel and the like. When desired, these preparations may
15 contain adjuvant, auxiliary substance, stabilizer, moistening agent, emulsifier, buffering agent, and other conventional additives. While the dose of the compound (I) varies depending on the age and symptom of patients, for the therapy of the above-mentioned diseases, an average single dose amount of about 0.1 mg,
20 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg or 1000 mg of the compound (I) would be effective. In general, its daily dose is from 0.1 mg/patient to about 1000 mg/patient.

The present invention is described in more detail by way of the following Preparation Examples and Examples.

25 **Preparation Example 1-1**

4,5-Dibromo-2-methylimidazole (4.91 g) was dissolved in N,N-dimethylformamide (50 ml), and 60% sodium hydride (901 mg) was added gradually under ice-cooling. After stirring at room temperature for 1 hour, 2-(trimethylsilyl)ethoxymethyl chloride
30 (3.75 g) was gradually added dropwise under ice-cooling, and the mixture was stirred overnight at room temperature. The solvent was evaporated under reduced pressure and ethyl acetate was added to the residue. The reaction mixture was washed with saturated aqueous sodium hydrogencarbonate solution and brine. The organic
35 layer was dried over anhydrous magnesium sulfate and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate=3/1) to

Preparation Example 3-2

In the same manner as in the aforementioned Preparation Example 2, 2-chloro-4-phenylbenzyl bromide was obtained as colorless crystals (3.22 g) from 2-chloro-4-phenyltoluene (3.6 g).
¹H-NMR(CDCl₃) : 4.64(2H, s), 7.35-7.63(8H, m).
 m.p. 73-74°C.

Preparation Example 4-1

2-Chloro-4-iodotoluene(22.0 g) was dissolved in N,N-dimethylformamide (110 ml), and copper(I) iodide (49.8 g), ethyl chlorodifluoroacetate (37.8 g) and potassium fluoride (15.2 g) were added. The mixture was stirred at internal temperature of 116°C for 70 hr. The reaction mixture was filtered through celite. Water (11 ml) and diethyl ether (110 ml) were added to the filtrate under ice-cooling and the mixture was filtered through celite. The filtrate was separated and the aqueous layer was extracted again with diethyl ether (110 ml). The organic layers were combined and washed with saturated brine (110 ml), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 2-chloro-4-trifluoromethyltoluene (23.0 g) as a brown oil.
¹H-NMR(CDCl₃) : 2.43(3H, s), 7.34(1H, d, J=8Hz), 7.42(1H, d, J=8Hz), 7.60(1H, s).

Preparation Example 4-2

In the same manner as in the aforementioned Preparation Example 2, 2-chloro-4-(trifluoromethyl)benzyl bromide (6.20 g) was obtained as a pale-yellow oil from 2-chloro-4-trifluoromethyltoluene (10.0 g).
¹H-NMR(CDCl₃) : 4.59(2H, s), 7.52(1H, d, J=8Hz), 7.57(1H, d, J=8Hz), 7.67(1H, s).

Preparation Example 5-1

3-Chloro-4-methylphenol (2.00 g) was dissolved in N,N-dimethylformamide (10.0 ml), and potassium carbonate (2.91 g) and 1-propyl iodide (2.62 g) were added. The mixture was stirred at room temperature for 20 hr, and the reaction mixture was concentrated under reduced pressure. Water was added, and the mixture was extracted with AcOEt. The organic layer was washed successively with water and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was applied to silica gel column chromatography and eluted with hexane:ethyl acetate=5:1. The objective fraction was

((cyclopentyl)methyloxy)toluene (1.46 g) as a colorless oil.

$^1\text{H-NMR}(\text{CDCl}_3)$: 1.22-1.93(8H, m), 2.29(3H, s), 2.34(1H, sept, $J=7\text{Hz}$), 3.78(2H, d, $J=7\text{Hz}$), 6.71(1H, dd, $J=8$ and 2Hz), 6.91(1H, d, $J=2\text{Hz}$), 7.09(1H, d, $J=8\text{Hz}$).

5 Preparation Example 7-2

In the same manner as in the aforementioned Preparation Example 2, 2-chloro-4-((cyclopentyl)methyloxy)benzyl bromide (2.06 g) was obtained as an oil from 2-chloro-4-((cyclopentyl)methyloxy)toluene (1.45 g).

10 $^1\text{H-NMR}(\text{CDCl}_3)$: 1.23-1.92(8H, m), 2.34(1H, sept, $J=7\text{Hz}$), 3.81(2H, d, $J=7\text{Hz}$), 4.59(2H, s), 6.78(1H, dd, $J=9$ and 2Hz), 6.93(1H, d, $J=2\text{Hz}$), 7.32(1H, d, $J=9\text{Hz}$).

Preparation Example 8-1

In the same manner as in the aforementioned Preparation Example 5-1, 2-chloro-4-((cyclohexyl)methyloxy)toluene (1.41 g) was obtained as colorless crystals from 3-chloro-4-methylphenol (926 mg).

15 $^1\text{H-NMR}(\text{CDCl}_3)$: 0.95-1.40(5H), 1.64-1.90(6H), 2.29(3H, s), 3.70(2H, d, $J=6\text{Hz}$), 6.70(1H, dd, $J=8$, 2Hz), 6.89(1H, d, $J=2\text{Hz}$), 7.08(1H, d, $J=8\text{Hz}$).

Preparation Example 8-2

In the same manner as in the aforementioned Preparation Example 2, 2-chloro-4-((cyclohexyl)methyloxy)benzyl bromide (1.35 g) was obtained as a pale-yellow solid from 2-chloro-4-((cyclohexyl)methyloxy)toluene (1.00 g).

25 $^1\text{H-NMR}(\text{CDCl}_3)$: 0.94-1.40(5H), 1.63-1.94(6H), 3.73(2H, d, $J=6\text{Hz}$), 4.59(2H, s), 6.79(1H, dd, $J=8$, 2Hz), 6.93(1H, d, $J=2\text{Hz}$), 7.32(1H, d, $J=8\text{Hz}$).

Preparation Example 9

30 To a solution of 4-bromo-2-chlorobenzyl alcohol (3.56 g) and anhydrous triethylamine (3 ml) in anhydrous dichloromethane (36 ml) was added dropwise methanesulfonyl chloride (1.4 ml) under ice-cooling in a nitrogen atmosphere. The mixture was stirred for 1 hr, and the reaction mixture was washed with water, saturated aqueous sodium hydrogencarbonate solution and saturated brine, and dried over anhydrous magnesium sulfate. The filtrate was concentrated to give 4-bromo-2-chloro-1-((methanesulfonyloxy)-methyl)benzene as a pale-brown solid (4.77 g).

35 $^1\text{H-NMR}(\text{CDCl}_3)$: 3.03(3H, s), 5.29(2H, s), 7.37(1H, d, $J=8\text{Hz}$), 7.47(1H, dd, $J=8$, 1Hz), 7.60(1H, d, $J=1\text{Hz}$).

Mass (ESI) : m/z 298 (M-1) .

Preparation Example 10-1

To a solution of methyl 4-bromo-2-chlorobenzoate (1.25 g) in N,N-dimethylformamide (10 ml) was added sodium thiomethoxide (459 mg) under ice-cooling and the mixture was stirred for 2 hr. To the reaction mixture was added 1N hydrochloric acid and the resulting product was extracted 3 times with diethyl ether. The organic layers were combined, washed successively with water and saturated brine and dried over anhydrous magnesium sulfate. The solvent was evaporated and the residue was applied to silica gel column chromatography (hexane/ethyl acetate=10/1) to give methyl 2-chloro-4-(methylthio)benzoate (835 mg) as a colorless oil.

¹H-NMR(CDCl₃) : 2.49 (3H, s), 3.90 (3H, s), 7.11 (1H, d, J=8Hz), 7.23 (1H, s), 7.78 (1H, d, J=8Hz).

15 Preparation Example 10-2

To a suspension of lithium aluminum hydride (139 mg) in tetrahydrofuran (8 ml) was added dropwise methyl 2-chloro-4-(methylthio)benzoate (806 mg) under ice-cooling, and the mixture was stirred for 1 hr. The reaction mixture was diluted with 20 diethyl ether and 1N hydrochloric acid (10 ml) was added dropwise. The resulting product was extracted 3 times with diethyl ether. The organic layers were combined and washed successively with saturated aqueous sodium hydrogencarbonate solution and saturated brine, and dried over anhydrous magnesium sulfate. The solvent 25 was evaporated to give 2-chloro-4-(methylthio)benzyl alcohol (725 mg) as a colorless oil.

$$^1\text{H-NMR}(\text{CDCl}_3) : 1.92(1\text{H}, \text{br t}, J=7\text{Hz}), 2.48(3\text{H}, \text{s}), 4.73(2\text{H}, \text{d}, J=7\text{Hz}), 7.15(1\text{H}, \text{d}, J=8\text{Hz}), 7.23(1\text{H}, \text{s}), 7.37(1\text{H}, \text{d}, J=8\text{Hz}).$$

Preparation Example 10-3

30 In the same manner as in the aforementioned Preparation
Example 9, 2-chloro-1-((methanesulfonyloxy)methyl)-4-
(methylthio)benzene (1.02 g) was obtained as a colorless oil from
2-chloro-4-(methylthio)benzyl alcohol (687 mg).
¹H-NMR(CDCl₃) : 2.48(3H, s), 3.00(3H, s), 5.30(2H, s), 7.15(1H, dd,
35 J=8 and 2Hz), 7.26(1H, d, J=2Hz), 7.38(1H, d, J=8Hz).

Preparation Example 11

In the same manner as in the aforementioned Preparation Example 9, 2-chloro-1-((methanesulfonyloxy)methyl)-4-nitrobenzene (3.56 g) was obtained as brown crystals from 2-chloro-4-nitrobenzyl alcohol (2.5 g).

¹H-NMR(CDCl₃) : 3.12(3H, s), 5.40(2H, s), 7.73(1H, d, J=8Hz), 8.18(1H, dd, J=2,8Hz), 8.79(1H, d, J=2Hz).

Preparation Example 12-1

4-Amino-2-chlorobenzoic acid (10.01 g) was homogeneously dissolved in 12.5% sulfuric acid (400 ml) by heating to 70°C and ice-cooled. To this suspension was added dropwise aqueous sodium nitrite solution (4.24 g/12 ml of water) at not more than 8°C over 5 min. After 5 min, this solution was gradually poured into water (500 ml) at 80°C, upon which the solution foamed vigorously and turned into a red solution. The reaction mixture was stirred at 80°C for 1 hr. After allowing to cool, the resulting product was extracted 3 times with diethyl ether. The organic layers were combined and washed successively with dil. hydrochloric acid, water and saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated and a small amount of diisopropyl ether was added to the residue to allow for crystallization to give 2-chloro-4-hydroxybenzoic acid (6.32 g) as an orange powder.

¹H-NMR(DMSO-d₆) : 6.79(1H, dd, J=8 and 2Hz), 6.88(1H, d, J=2Hz),
20 7.77(1H, d, J=8Hz).

Mass (ESI) : m/e 171 (M-H)-.

Preparation Example 12-2

To a solution of 2-chloro-4-hydroxybenzoic acid (695 mg) in N,N-dimethylformamide (3.5 ml) were added potassium carbonate (1.67 g) and benzyl bromide (1.73 g) and the mixture was stirred at room temperature for 14 hr. To the reaction mixture was added 1N hydrochloric acid and the resulting product was extracted 3 times with diethyl ether. The organic layers were combined and washed successively with water, saturated aqueous sodium hydrogencarbonate solution and saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated and the residue was recrystallized from diisopropyl ether/hexane to give benzyl 4-benzyloxy-2-chlorobenzoate (1.13 g) as a pale-yellow powder.

¹H-NMR(CDCl₃) : 5.09(2H, s), 5.32(2H, s), 6.87(1H, dd, J=8 and 2Hz), 7.05(1H, d, J=2Hz), 7.29-7.50(10H, m), 7.91(1H, d, J=8Hz).

Mass (ESI) : m/e 353 (M+H)+.

Preparation Example 12-3

To benzyl 4-benzyloxy-2-chlorobenzoate (1.12 g) were added
40 ethanol (8.8 ml), 1,4-dioxane (2.2 ml) and 1N aqueous sodium

hydroxide solution (4.7 ml) and the mixture was stirred at 70°C for 1.5 hr. The solvent was evaporated and water was added to the residue for dissolution, which was washed with diethyl ether. The aqueous layer was acidified with 1N hydrochloric acid and the
5 precipitate was collected by filtration to give 4-benzyloxy-2-chlorobenzoic acid (810 mg) as a pale-yellow powder.

¹H-NMR(DMSO-d₆) : 5.20(2H, s), 7.06(1H, dd, J=8 and 2Hz), 7.18(1H, d, J=2Hz), 7.29-7.50(5H, m), 7.82(1H, d, J=8Hz).

Mass (ESI) : m/e 261 (M-H) -.

10 Preparation Example 12-4

To a solution of 4-benzyloxy-2-chlorobenzoic acid (788 mg) in tetrahydrofuran (7.9 ml) was added dropwise borane-dimethylsulfide complex (10.0M, 0.6 ml) at room temperature under a nitrogen atmosphere and the mixture was refluxed under heating
15 for 2.5 hr. The reaction mixture was allowed to cool to room temperature, and 1N hydrochloric acid (1.5 ml) was carefully added dropwise. The mixture was stirred for 30 min. To the reaction mixture was added water and the resulting product was extracted 3 times with ethyl acetate. The organic layers were combined,

20 washed successively with saturated aqueous sodium hydrogencarbonate solution and saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated to give 4-benzyloxy-2-chlorobenzyl alcohol (778 mg) as a white powder.

$^1\text{H-NMR}(\text{CDCl}_3)$: 1.83(1H, br t, $J=7\text{Hz}$), 4.70(2H, d, $J=7\text{Hz}$), 5.05(2H, s), 6.88(1H, dd, $J=8$ and 2Hz), 7.01(1H, d, $J=2\text{Hz}$), 7.28-7.46(6H, m).

Preparation Example 12-5

In the same manner as in the aforementioned Preparation Example 9, 4-benzyloxy-2-chlorobenzyl chloride (639 mg) was
30 obtained as a colorless oil from 4-benzyloxy-2-chlorobenzyl alcohol (523 mg).

¹H-NMR(CDCl₃) : 4.67(2H, s), 5.05(2H, s), 6.87(1H, dd, J=8 and 2Hz), 7.02(1H, d, J= 2Hz), 7.28-7.44(6H, m).

Preparation Example 13-1

35 To a solution of 4-bromo-2-chlorobenzyl alcohol (14.48 g)
in N,N-dimethylformamide (72 ml) were added imidazole (5.34 g) and
tert-butylchlorodiphenylsilane (19.8 g) under ice-cooling, and the
mixture was stirred for 1 hr. Water was added to the reaction
mixture and the resulting product was extracted twice with hexane.
40 The organic layers were combined, washed successively with water,

CONFIDENTIAL

butyldiphenylsiloxy)methyl)-3-chlorobenzyl alcohol (3.08 g) as a colorless oil.

$^1\text{H-NMR}(\text{CDCl}_3)$: 1.12(9H, s), 1.70(1H, br t, $J=5\text{Hz}$), 4.69(2H, d, $J=5\text{Hz}$), 4.83(2H, s), 7.27-7.50(8H, m), 7.65-7.78(5H, m).

5 **Preparation Example 13-4**

In the same manner as in the aforementioned Preparation Example 9, 1-((tert-butyldiphenylsiloxy)methyl)-2-chloro-4-((methanesulfonyloxy)methyl)benzene (3.80 g) was obtained as a colorless oil from 4-((tert-butyldiphenylsiloxy)methyl)-3-

10 chlorobenzyl alcohol (3.05 g).

$^1\text{H-NMR}(\text{CDCl}_3)$: 1.12(9H, s), 2.97(3H, s), 4.83(2H, s), 5.21(2H, s), 7.33-7.50(8H, m), 7.63-7.75(4H, m), 7.77-7.83(1H, m).

Preparation Example 13-5

To a solution of phenol (969 mg) in N,N-dimethylformamide

15 (27 ml) was added potassium carbonate powder (1.92 g) and the mixture was stirred at room temperature for 5 min. 1-((tert-Butyldiphenylsiloxy)methyl)-2-chloro-4-((methanesulfonyloxy)-methyl)benzene (3.39 g) was added and the mixture was stirred at 100°C for 3 hr. The reaction mixture was allowed to cool to room

20 temperature. Water was added and the mixture was extracted twice with hexane. The organic layers were combined, washed successively with water and saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated and the residue was purified by column chromatography (silica gel,

25 hexane/ethyl acetate=50/1) to give 1-((tert-butyldiphenylsiloxy)-methyl)-2-chloro-4-(phoxymethyl)benzene (2.65 g) as a colorless oil.

$^1\text{H-NMR}(\text{CDCl}_3)$: 1.12(9H, s), 4.83(2H, s), 5.04(2H, s), 6.93-7.04(3H, m), 7.25-7.50(10H, m), 7.65-7.73(4H, m), 7.73-7.80(1H, m).

30 **Preparation Example 13-6**

To a solution of 1-((tert-butyldiphenylsiloxy)methyl)-2-chloro-4-(phoxymethyl)benzene (2.84 g) in tetrahydrofuran (14 ml) was added tetrabutyl ammonium fluoride/tetrahydrofuran solution (1.0 M, 7.0 ml) under ice-cooling and the mixture was

35 stirred for 1.5 hr. Water was added to the reaction mixture and the resulting product was extracted twice with ethyl acetate. The organic layers were combined, washed successively with 1N hydrochloric acid, saturated aqueous sodium hydrogencarbonate solution and saturated brine, and dried over anhydrous magnesium

40 sulfate. The solvent was evaporated and the residue was purified

by silica gel column chromatography (hexane/ethyl acetate=5/1) to give 2-chloro-4-(phoxymethyl)benzyl alcohol (1.38 g) as a white powder.

¹H-NMR(CDCl₃) : 1.92(1H, br t, J=6Hz), 4.79(2H, d, J=6Hz), 5.05(2H, s), 6.88-7.06(3H, m), 7.23-7.40(3H, m), 7.42-7.57(2H, m).

Preparation Example 13-7

In the same manner as in the aforementioned Preparation Example 9, 2-chloro-1-((methanesulfonyloxy)methyl)-4-(phoxymethyl)benzene (1.83 g) was obtained as an oil from 2-chloro-4-(phoxymethyl)benzyl alcohol (1.36 g).

¹H-NMR(CDCl₃) : 3.03(3H, s), 5.07(2H, s), 5.35(2H, s), 6.91-7.04(3H, m), 7.25-7.42(3H, m), 7.44-7.67(2H, m).

Preparation Example 14-1

In the same manner as in the aforementioned Preparation Example 12-4, 3-chloro-4-methylbenzyl alcohol (23.0 g) was obtained as a colorless oil from 3-chloro-4-methylbenzoic acid (25.0 g).

¹H-NMR(CDCl₃) : 2.36(3H, s), 4.65(2H, s), 7.14(1H, d, J=8Hz), 7.23(1H, d, J=8Hz), 7.36(1H, s).

Preparation Example 14-2

To a solution of 3-chloro-4-methylbenzyl alcohol (2.00 g) and triethylamine (8.9 ml) in dimethyl sulfoxide (10 ml) was added sulfur trioxide-pyridine complex (4.47 g) under water-cooling. The mixture was stirred at room temperature for 3 hr. The reaction mixture was poured into ice water and the mixture was extracted with diethyl ether. The organic layer was washed with 1N hydrochloric acid, saturated brine and saturated aqueous sodium hydrogencarbonate solution and dried over magnesium sulfate. The residue was concentrated to dryness under reduced pressure to give 3-chloro-4-methylbenzaldehyde (1.40 g) as a pale-yellow oil.

¹H-NMR(CDCl₃) : 2.46(3H, s), 4.65(2H, s), 7.40(1H, d, J=8Hz), 7.68(1H, d, J=8Hz), 9.92(1H, s).

Preparation Example 14-3

In the same manner as in Preparation Example 15-2 to be mentioned later, (E)-2-chloro-4-(2-phenylethenyl)toluene (1.55 g) was obtained as a white powder from 3-chloro-4-methylbenzaldehyde (1.40 g) and diethyl benzylphosphonate (2.27 g).

¹H-NMR(CDCl₃) : 2.38(3H, s), 7.00(1H, d, J=16Hz), 7.08(1H, d, J=16Hz), 7.18-7.53(8H).

Preparation Example 14-4

In the same manner as in the aforementioned Preparation Example 2, (E)-2-chloro-4-(2-phenylethenyl)benzyl bromide (309 mg) was obtained as a white powder from (E)-2-chloro-4-(2-phenylethenyl)toluene (1.35 g).

$^1\text{H-NMR}(\text{CDCl}_3)$: 4.61 (2H, s), 7.01 (1H, d, $J=16\text{Hz}$), 7.14 (1H, d, $J=16\text{Hz}$), 7.24-7.57 (8H).

Preparation Example 15-1

To a solution of 5-chloro-2-methylimidazole-4-carbaldehyde (433 mg) in N,N-dimethylformamide (4.3 ml) were added potassium carbonate powder (616 mg) and 2-chloro-4-iodobenzyl bromide (1.2 equivalents) under ice-cooling and the mixture was stirred at room temperature for 2.5 hr. To the reaction mixture were added water and saturated brine, and the resulting product was extracted twice with ethyl acetate. The organic layers were combined, washed with saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated and the residue was purified by silica gel column chromatography (hexane/ethyl acetate=5/1) to give 4-chloro-1-(2-chloro-4-iodobenzyl)-2-methylimidazole-5-carbaldehyde (1.01 g) as a white powder.

$^1\text{H-NMR}(\text{CDCl}_3)$: 2.33 (3H, s), 5.56 (2H, s), 6.21 (1H, d, $J=8\text{Hz}$), 7.50 (1H, dd, $J=8$ and 2Hz), 7.78 (1H, d, $J=2\text{Hz}$), 9.75 (1H, s).

Mass (ESI) : m/e 395 (M+H)+.

Preparation Example 15-2

To a solution of 4-chloro-1-(2-chloro-4-iodobenzyl)-2-methylimidazole 5-carbaldehyde (1.01 g) in tetrahydrofuran (10 ml) was added methyl (triphenylphosphoranylidene)acetate (1.27 g) and the mixture was refluxed under heating for 4 hr. The solvent was evaporated and the residue was purified by silica gel column chromatography (hexane/ethyl acetate=3/1) to give methyl (E)-3-(4-chloro-1-(2-chloro-4-iodobenzyl)-2-methylimidazol-5-yl)-2-propionate (974 mg) as a white powder.

$^1\text{H-NMR}(\text{CDCl}_3)$: 2.33 (3H, s), 3.75 (3H, s), 5.15 (2H, s), 6.17 (1H, d, $J=8\text{Hz}$), 6.49 (1H, d, $J=16\text{Hz}$), 7.28 (1H, d, $J=16\text{Hz}$), 7.53 (1H, dd, $J=8$ and 2Hz), 7.81 (1H, d, $J=2\text{Hz}$).

Mass (ESI) : m/e 451 (M+H)+.

Preparation Example 15-3

A mixture of tetrakis(triphenylphosphine)palladium(0) (89 mg), methyl (E)-3-(4-chloro-1-(2-chloro-4-iodobenzyl)-2-methylimidazol-5-yl)-2-propionate (350 mg), 2-furylboronic acid

J=8Hz), 6.51(1H, d, J=16Hz), 7.07-7.11(1H, m), 7.29-7.38(3H, m), 7.41(1H, dd, J=2, 8Hz), 7.69(1H, d, J=2Hz).

Mass(ESI) : m/z 407(M+1).

Preparation Example 16-2

5 In the same manner as in the aforementioned Preparation Example 15-4, (E)-3-(4-chloro-1-(2-chloro-4-(2-thienyl)benzyl)-2-methylimidazol-5-yl)-2-propenic acid was obtained as pale-yellow crystals (231 mg) from methyl (E)-3-(4-chloro-1-(2-chloro-4-(2-thienyl)benzyl)-2-methylimidazol-5-yl)-2-propenate (281 mg).

10 ¹H-NMR(DMSO-d₆) : 2.34(3H, s), 5.42(2H, s), 6.27(1H, d, J=16Hz), 6.55(1H, d, J=8Hz), 7.12-7.19(1H, m), 7.25(1H, d, J=16Hz), 7.52-7.62(3H, m), 7.87(1H, d, J=2Hz).

Mass(ESI) : m/z 391(M-1).

Preparation Example 17-1

15 To a mixture of methyl (E)-3-(4-chloro-1-(2-chloro-4-iodobenzyl)-2-methylimidazol-5-yl)-2-propenate (360 mg), dichlorobis(triphenylphosphine)palladium(II) (28 mg) and copper iodide (7.6 mg) was added a solution of phenylacetylene (326 mg) in diisopropylamine (20 ml) in a nitrogen atmosphere and the mixture was refluxed under heating for 5 hr. The reaction mixture was allowed to cool. Water was added and the mixture was extracted twice with chloroform. The organic layers were combined, washed with saturated aqueous sodium hydrogencarbonate solution and saturated brine, and dried over anhydrous magnesium sulfate.

25 The resultant was filtrated under reduced pressure and concentrated to give a crude product. The product was applied to flash silica gel column chromatography (silica gel 10 g) to give methyl (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-2-propenate as brown amorphous (331 mg) from the eluted fraction of hexane/ethyl acetate=5/1 - 1-1.

30 ¹H-NMR(CDCl₃) : 2.35(3H, s), 3.75(3H, s), 5.23(2H, s), 6.45(1H, d, J=8Hz), 6.50(1H, d, J=16Hz), 7.27-7.40(5H, m), 7.48-7.56(2H, m), 7.63(1H, s).

Mass(ESI) : m/z 425(M+1).

35 Preparation Example 17-2

In the same manner as in the aforementioned Preparation Example 15-4, (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-2-propenic acid was obtained as pale-ocher crystals (283 mg) from methyl (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-2-propenate

(413 mg).

¹H-NMR(CDCl₃) : 2.36(3H, s), 5.23(2H, s), 6.45(1H, d, J=8Hz), 6.48(1H, d, J=16Hz), 7.32-7.41(5H, m), 7.48-7.55(2H, m), 7.64(1H, d, J=2Hz).

5 Mass(ESI) : m/z 409(M-1).

Preparation Example 18-1

In the same manner as in the aforementioned Preparation Example 15-1, 1-(4-bromo-2-chlorobenzyl)-4-chloro-2-methylimidazole-5-carbaldehyde (430 mg) was obtained as pale-
10 yellow crystals from 4-chloro-2-methylimidazole-5-carbaldehyde (200 mg) and 4-bromo-2-chloro-1-((methanesulfonyloxy)-methyl)benzene (456 mg).

¹H-NMR(CDCl₃) : 2.33(3H, s), 5.56(2H, s), 6.38(1H, d, J=8Hz), 7.31(1H, dd, J=8, 2Hz), 7.60(1H, d, J=2Hz), 9.75(1H, s).

15 Preparation Example 18-2

In the same manner as in the aforementioned Preparation Example 15-2, methyl (E)-3-(1-(4-bromo-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-2-propenate (372 mg) was obtained as colorless crystals from 1-(4-bromo-2-chlorobenzyl)-4-chloro-2-
20 methylimidazole 5-carbaldehyde (394 mg) and methyl (triphenylphosphoranylidene)acetate (606 mg).

¹H-NMR(CDCl₃) : 2.33(3H, s), 3.75(3H, s), 5.16(2H, s), 6.33(1H, d, J=8Hz), 6.50(1H, d, J=15Hz), 7.26(1H, d, J=2Hz), 7.34(1H, dd, J=8, 2Hz), 7.63(1H, d, J=2Hz).

25 Preparation Example 18-3

In the same manner as in the aforementioned Preparation Example 15-4, (E)-3-(1-(4-bromo-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-2-propenic acid (338 mg) was obtained as pale-yellow crystals from methyl (E)-3-(1-(4-bromo-2-
30 chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-2-propenate (355 mg).

¹H-NMR(DMSO-d₆) : 2.31(3H, s), 5.38(2H, s), 6.26(1H, d, J=15Hz), 6.45(1H, d, J=8Hz), 7.21(1H, d, J=15Hz), 7.53(1H, dd, J=8, 2Hz), 7.87(1H, d, J=2Hz).

Preparation Example 19-1

35 In the same manner as in the aforementioned Preparation Example 15-1, 4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazole-5-carbaldehyde (1.23 g) was obtained as a colorless oil from 5-chloro-2-methylimidazole-4-carbaldehyde (600 mg) and 2-chloro-4-phenylbenzyl bromide (1.4 g).

40 ¹H-NMR(CDCl₃) : 2.36(3H, s), 5.67(2H, s), 6.56(1H, d, J=8Hz), 7.35-

7.55(6H), 7.65(1H, s), 9.80(1H, s).

Preparation Example 19-2

In the same manner as in the aforementioned Preparation Example 15-2, methyl (E)-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-2-propenate (1.13 g) was obtained as a white powder from 4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazole-5-carbaldehyde (1.23 g).

¹H-NMR(CDCl₃) : 2.37(3H, s), 3.74(3H, s), 5.25(2H, s), 6.46-6.57(2H), 7.30-7.55(7H), 7.68(1H, s).

Preparation Example 19-3

In the same manner as in the aforementioned Preparation Example 15-4, (E)-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-2-propenic acid (1.18 g) was obtained as a white powder from methyl (E)-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-2-propenate (1.35 g).

¹H-NMR(DMSO-d₆) : 2.35(3H, s), 5.45(2H, s), 6.30(1H, d, J=16Hz), 6.58(1H, d, J=8Hz), 7.25(1H, d, J=16Hz), 7.36-7.52(3H), 7.62(1H, d, J=8Hz), 7.69(2H, d, J=8Hz), 7.86(1H, s).

Preparation Example 20-1

In the same manner as in the aforementioned Preparation Example 15-1, 4-chloro-1-(2-chloro-4-(1-propoxy)benzyl)-2-methylimidazole-5-carbaldehyde (376 mg) was obtained as pale-yellow crystals from 4-chloro-2-methylimidazole-5-carbaldehyde (200 mg) and 2-chloro-4-(1-propoxy)benzyl bromide (474 mg).

¹H-NMR(CDCl₃) : 1.02(3H, t, J=7Hz), 1.73-1.85(2H, m), 2.32(3H, s), 3.87(2H, t, J=7Hz), 5.57(2H, s), 6.46(1H, d, J=8Hz), 6.70(1H, dd, J=8, 2Hz), 6.96(1H, d, J=2Hz), 9.77(1H, s).

Preparation Example 20-2

In the same manner as in the aforementioned Preparation Example 15-2, methyl (E)-3-(4-chloro-1-(2-chloro-4-(1-propoxy)benzyl)-2-methylimidazol-5-yl)-2-propenate (348 mg) was obtained as colorless crystals from 4-chloro-1-(2-chloro-4-(1-propoxy)benzyl)-2-methylimidazole-5-carbaldehyde (356 mg) and methyl (triphenylphosphoranylidene)acetate (546 mg).

¹H-NMR(CDCl₃) : 1.02(3H, t, J=7Hz), 1.74-1.85(2H, m), 2.34(3H, s), 3.75(3H, s), 3.89(2H, t, J=7Hz), 5.15(2H, s), 6.37(1H, d, J=8Hz), 6.49(1H, d, J=15Hz), 6.71(1H, dd, J=8, 2Hz), 6.99(1H, d, J=2Hz), 7.34(1H, d, J=15Hz).

Preparation Example 20-3

In the same manner as in the aforementioned Preparation

Example 15-4, (E)-3-(4-chloro-1-(2-chloro-4-(1-propoxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (305 mg) was obtained as colorless crystals from methyl (E)-3-(4-chloro-1-(2-chloro-4-(1-propoxy)benzyl)-2-methylimidazol-5-yl)-2-propenate (332 mg).

Preparation Example 21-1

15 $^1\text{H-NMR}(\text{CDCl}_3)$: 0.93(3H, t, $J=6\text{Hz}$), 1.40(4H, m), 1.76(2H, m), 2.32(3H, s), 3.90(2H, t, $J=6\text{Hz}$), 5.57(2H, s), 6.45(1H, d, $J=8\text{Hz}$), 6.70(1H, dd, $J=8, 2\text{Hz}$), 6.95(1H, d, $J=2\text{Hz}$), 9.76(1H, s).

In the same manner as in the aforementioned Preparation

¹H-NMR(CDCl₃) : 0.93(3H, t, J=7Hz), 1.32-1.49(4H, m), 1.71-1.83(2H, m), 2.34(3H, s), 3.75(3H, s), 3.92(2H, t, J=7Hz), 5.15(2H, s), 6.37(1H, d, J=8Hz), 6.49(1H, d, J=16Hz), 6.70(1H, dd, J=2, 8Hz), 6.99(1H, d, J=2Hz), 7.34(1H, d, J=16Hz).

Preparation Example 21-3

¹H-NMR(CDCl₃) : 0.92(3H, t, J=7Hz), 1.30-1.50(4H, m), 1.70-1.83(2H, m), 2.36(3H, s), 3.92(2H, t, J=7Hz), 5.16(2H, s), 6.38(1H, d, J=8Hz), 6.47(1H, d, J=16Hz), 6.71(1H, dd, J=2, 8Hz), 6.99(1H, d, J=2Hz), 7.40(1H, d, J=16Hz).

38

CONFIDENTIAL

Preparation Example 22-1

In the same manner as in the aforementioned Preparation Example 15-1, 4-chloro-1-(2-chloro-4-((cyclopentyl)methoxy)-benzyl)-2-methylimidazole-5-carbaldehyde (608 mg) was obtained as
5 a colorless oil from 5-chloro-2-methylimidazole-4-carbaldehyde (300 mg) and 2-chloro-4-((cyclopentyl)methoxy)benzyl bromide (764 mg).

$^1\text{H-NMR}(\text{CDCl}_3)$: 1.22-1.92(8H, m), 2.32(3H, s), 2.33(1H, sept, J=7Hz), 3.78(2H, d, J=7Hz), 5.57(2H, s), 6.45(1H, d, J=8Hz),
10 6.70(1H, dd, J=9 and 2Hz), 6.96(1H, d, J=2Hz), 9.77(1H, s).
Mass(ESI) : m/e 367(M+H)+.

Preparation Example 22-2

In the same manner as in the aforementioned Preparation Example 15-2, methyl (E)-3-(4-chloro-1-(2-chloro-4-
15 ((cyclopentyl)methoxy)benzyl)-2-methylimidazol-5-yl)-2-propenate (563 mg) was obtained as a white powder from 4-chloro-1-(2-chloro-4-((cyclopentyl)methoxy)benzyl)-2-methylimidazole-5-carbaldehyde (577 mg) and methyl (triphenylphosphoranylidene)acetate (788 mg).

$^1\text{H-NMR}(\text{CDCl}_3)$: 1.24-1.92(8H, m), 2.34(3H, s), 2.34(1H, sept, J=7Hz), 3.74(3H, s), 3.79(2H, d, J=7Hz), 5.15(2H, s), 6.37(1H, d, J=8Hz), 6.49(1H, d, J=16Hz), 6.71(1H, dd, J=8 and 3Hz), 6.99(1H, d, J=3Hz), 7.34(1H, d, J=16Hz).
20 Mass(ESI) : m/e 423(M+H)+.

Preparation Example 22-3

25 In the same manner as in the aforementioned Preparation Example 15-4, (E)-3-(4-chloro-1-(2-chloro-4-((cyclopentyl)-methoxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (532 mg) was obtained as a white powder from methyl (E)-3-(4-chloro-1-(2-chloro-4-((cyclopentyl)methoxy)benzyl)-2-methylimidazol-5-yl)-2-
30 propenate (535 mg).

$^1\text{H-NMR}(\text{CDCl}_3)$: 1.23-1.92(8H, m), 2.33(1H, sept, J=7Hz), 2.35(3H, s), 3.79(2H, d, J=7Hz), 5.15(2H, s), 6.37(1H, d, J=8Hz), 6.46(1H, d, J=16Hz), 6.71(1H, dd, J=8 and 2Hz), 6.99(1H, d, J=2Hz), 7.40(1H, d, J=16Hz).
35 Mass(ESI) : m/e 407(M-H)-.

Preparation Example 23-1

In the same manner as in the aforementioned Preparation Example 15-1, 4-chloro-1-(2-chloro-4-((cyclohexyl)methoxy)-benzyl)-2-methylimidazole-5-carbaldehyde was obtained as a yellow
40 oil (410 mg) from 5-chloro-2-methylimidazole-4-carbaldehyde (200

[illegible]

¹H-NMR(CDCl₃) : 2.33(3H, s), 3.75(3H, s), 5.03(2H, s), 5.15(2H, s), 6.38(1H, d, J=8Hz), 6.50(1H, d, J=16Hz), 6.79(1H, dd, J=2, 8Hz), 7.08(1H, d, J=2Hz), 7.33(1H, d, J=16Hz), 7.31-7.43(5H, m).

Preparation Example 24-3

¹H-NMR(CDCl₃) : 2.35(3H, s), 5.03(2H, s), 5.16(2H, s), 6.40(1H, d, J=8Hz), 6.47(1H, d, J=16Hz), 6.80(1H, dd, J=2, 8Hz), 7.09(1H, d, J=2Hz), 7.30-7.45(6H, m).

Preparation Example 25-1

¹H-NMR(CDCl₃) : 2.32(3H, s), 2.46(3H, s), 5.58(2H, s), 6.43(1H, d, J=8Hz), 7.03(1H, dd, J=2, 8Hz), 7.26(1H, overlapped with CDCl₃),

Mass (ESI) : m/z 315 (M+1).

¹H-NMR(CDCl₃) : 2.34 (3H, s), 2.47 (3H, s), 3.75 (3H, s), 5.17 (2H, s), 6.36 (1H, d, J=8Hz), 6.49 (1H, d, J=16Hz), 7.04 (1H, dd, J=2, 8Hz),

41

Mass(ESI) : m/z 371(M+1).

Preparation Example 25-3

In the same manner as in the aforementioned Preparation Example 15-4, (E)-3-(4-chloro-1-(2-chloro-4-(methylthio)benzyl)-2-methylimidazol-5-yl)-2-propenic acid was obtained as thin yellow crystals (305 mg) from methyl (E)-3-(4-chloro-1-(2-chloro-4-(methylthio)benzyl)-2-methylimidazol-5-yl)-2-propenate (374 mg).
¹H-NMR(CDCl₃) : 2.35 (3H, s), 2.47(3H, s), 5.18(2H, s), 6.38(1H, d, J=8Hz), 6.47(1H, d, J=16Hz), 7.05(1H, dd, J=2, 8Hz), 7.30(1H, d, J=2Hz), 7.37(1H, d, J=16Hz).

Mass(ESI) : m/z 357(M+1).

Preparation Example 26-1

In the same manner as in the aforementioned Preparation Example 15-1, 4-chloro-1-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylimidazole-5-carbaldehyde (189 mg) was obtained as a pale-yellow solid from 5-chloro-2-methylimidazole-4-carbaldehyde (100 mg) and 2-chloro-4-(trifluoromethyl)benzyl bromide (378 mg).
¹H-NMR(CDCl₃) : 2.35(3H, s), 5.65(2H, s), 6.60(1H, d, J=8Hz), 7.45(1H, d, J=8Hz), 7.71(1H, s), 9.76(1H, s).

Mass(ESI) : m/e 337(M)+.

Preparation Example 26-2

In the same manner as in the aforementioned Preparation Example 15-2, ethyl (E)-3-[4-chloro-1-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylimidazol-5-yl]-2-propenate (207 mg) was obtained as a colorless oil from 4-chloro-1-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylimidazole-5-carbaldehyde (185 mg).
¹H-NMR(CDCl₃) : 1.30(3H, t, J=6Hz), 2.35(3H, s), 4.20(2H, q, J=6Hz), 5.36(2H, s), 6.54(1H, d, J=16Hz), 6.59(1H, d, J=8Hz), 7.26(1H, d, J=16Hz), 7.48(1H, d, J=8Hz), 7.75(1H, s).

Mass(ESI) : m/e 408(M+H)+.

Preparation Example 26-3

In the same manner as in the aforementioned Preparation Example 15-4, (E)-3-(4-chloro-1-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylimidazol-5-yl)-2-propenic acid was obtained as colorless crystals (144 mg) from ethyl (E)-3-(4-chloro-1-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylimidazol-5-yl)-2-propenate (203 mg).

¹H-NMR(CDCl₃) : 2.36(3H, s), 5.26(2H, s), 6.49(1H, d, J=16Hz), 6.60(1H, d, J=8Hz), 7.33(1H, d, J=16Hz), 7.49(1H, d, J=8Hz), 7.75(1H, s).

Mass (ESI) : m/z 379 (M+1).

Preparation Example 27-1

In the same manner as in the aforementioned Preparation Example 15-1, 4-chloro-1-(2-chloro-4-(phenoxyethyl)benzyl)-2-methylimidazole-5-carbaldehyde (482 mg) was obtained as a colorless oil from 5-chloro-2-methylimidazole-4-carbaldehyde (216 mg) and 2-chloro-1-((methanesulfonyloxy)methyl)-4-(phenoxyethyl)benzene (605 mg).

¹H-NMR(CDCl₃) : 2.33(3H, s), 5.01(2H, s), 5.63(2H, s), 6.51(1H, d, J=8Hz), 6.90-7.03(3H, m), 7.20-7.35(3H, m), 7.53(1H, d, J=2Hz), 9.77(1H, s).

Mass (ESI) : m/e 375 (M+H)+.

Preparation Example 27-2

In the same manner as in the aforementioned Preparation
15 Example 15-2, methyl (E)-3-(4-chloro-1-(2-chloro-4-
(phenoxyethyl)benzyl)-2-methylimidazol-5-yl)-2-propenoate (413 mg)
was obtained as a white powder from 4-chloro-1-(2-chloro-4-
(phenoxyethyl)benzyl)-2-methylimidazole-5-carbaldehyde (475 mg)
and methyl (triphenylphosphoranylidene)acetate (623 mg).

¹H-NMR(CDCl₃) : 2.34(3H, s), 3.74(3H, s), 5.03(2H, s), 5.22(2H, s), 6.47(1H, d, J=8Hz), 6.50(1H, d, J=16Hz), 6.91-7.04(3H, m), 7.21-7.34(3H, m), 7.22(1H, d, J=16Hz), 7.57(1H, d, J=2Hz).

Mass (ESI) : m/e 431 (M+H)+.

Preparation Example 27-3

25 In the same manner as in the aforementioned Preparation
Example 15-4, (E)-3-(4-chloro-1-(2-chloro-4-(phenoxyethyl)-
benzyl)-2-methylimidazol-5-yl)-2-propenoic acid (391 mg) was
obtained as a white powder from methyl (E)-3-(4-chloro-1-(2-
chloro-4-(phenoxyethyl)benzyl)-2-methylimidazol-5-yl)-2-propenoate
30 (404 mg).

$$^1\text{H-NMR}(\text{CDCl}_3) : 2.34(3\text{H}, \text{s}), 5.01(2\text{H}, \text{s}), 5.21(2\text{H}, \text{s}), 6.46(1\text{H}, \text{d}, J=16\text{Hz}), 6.47(1\text{H}, \text{d}, J=9\text{Hz}), 6.89-7.02(3\text{H}, \text{m}), 7.20-7.34(3\text{H}, \text{m}), 7.34(1\text{H}, \text{d}, J=16\text{Hz}), 7.55(1\text{H}, \text{d}, J=2\text{Hz}).$$

Mass(ESI) : m/e 415(M-H)-.

35 Preparation Example 28-1

In the same manner as in the aforementioned Preparation Example 15-1, 4-chloro-1-(2-chloro-4-nitrobenzyl)-2-methylimidazole-5-carbaldehyde (304 mg) was obtained as pale-yellow crystals from 4-chloro-2-methylimidazole-5-carbaldehyde (200 mg) and 2-chloro-1-((methanesulfonyloxy)methyl)-4-

nitrobenzene (404 mg).

$^1\text{H-NMR}$ (CDCl_3) : 2.37 (3H, s), 5.67 (2H, s), 6.67 (1H, d, $J=8\text{Hz}$), 8.06 (1H, dd, $J=8, 2\text{Hz}$), 8.34 (1H, d, $J=2\text{Hz}$), 9.75 (1H, s).

Preparation Example 28-2

5 In the same manner as in the aforementioned Preparation Example 15-2, methyl (E)-3-(4-chloro-1-(2-chloro-4-nitrobenzyl)-2-methylimidazol-5-yl)-2-propenate (297 mg) was obtained as pale-yellow crystals from 4-chloro-1-(2-chloro-4-nitrobenzyl)-2-methylimidazole-5-carbaldehyde (285 mg) and methyl
10 (triphenylphosphoranylidene)acetate (546 mg).

$^1\text{H-NMR}$ (CDCl_3) : 2.35 (3H, s), 3.74 (3H, s), 5.29 (2H, s), 6.52 (1H, d, $J=15\text{Hz}$), 6.65 (1H, d, $J=8\text{Hz}$), 7.27 (1H, d, $J=2\text{Hz}$), 8.08 (1H, d, $J=8, 2\text{Hz}$), 8.36 (1H, d, $J=2\text{Hz}$).

Preparation Example 28-3

15 In the same manner as in the aforementioned Preparation Example 15-4, (E)-3-(4-chloro-1-(2-chloro-4-nitrobenzyl)-2-methylimidazol-5-yl)-2-propenic acid (233 mg) was obtained as pale-orange crystals from methyl (E)-3-(4-chloro-1-(2-chloro-4-nitrobenzyl)-2-methylimidazol-5-yl)-2-propenate (275 mg).

20 $^1\text{H-NMR}$ ($\text{DMSO}-d_6$) : 2.32 (3H, s), 5.56 (2H, s), 6.28 (1H, d, $J=15\text{Hz}$), 6.77 (1H, d, $J=8\text{Hz}$), 7.22 (1H, d, $J=15\text{Hz}$), 8.16 (1H, dd, $J=8, 2\text{Hz}$), 8.41 (1H, d, $J=2\text{Hz}$).

Preparation Example 29-1

In the same manner as in the aforementioned Preparation
25 Example 15-1, (E)-4-chloro-1-(2-chloro-4-(2-phenylethenyl)benzyl)-2-methylimidazole-5-carbaldehyde was obtained as orange crystals (471 mg) from 5-chloro-2-methylimidazole-4-carbaldehyde (209 mg) and (E)-2-chloro-4-(2-phenylethenyl)benzyl bromide (489 mg).

$^1\text{H-NMR}$ (CDCl_3) : 2.34 (3H, s), 5.64 (2H, s), 6.50 (1H, d, $J=8\text{Hz}$),
30 6.99 (1H, d, $J=16\text{Hz}$), 7.10 (1H, d, $J=16\text{Hz}$), 7.25-7.42 (4H, m), 7.50 (2H, d, $J=8\text{Hz}$), 7.58 (2H, s), 9.78 (1H, s).

Mass (ESI) : m/z 371 ($M+1$).

Preparation Example 29-2

In the same manner as in the aforementioned Preparation
35 Example 15-2, methyl (2E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-2-propenate was obtained as yellow amorphous (433 mg) from (E)-4-chloro-1-(2-chloro-4-(2-phenylethenyl)benzyl)-2-methylimidazole-5-carbaldehyde (390 mg).

40 $^1\text{H-NMR}$ (CDCl_3) : 2.36 (3H, s), 3.74 (3H, s), 5.22 (2H, s), 6.45 (1H, d,

6.58(1H, d, J=8Hz), 7.24(1H, d, J=15Hz), 7.65(1H, t, J=8Hz), 7.76(1H, t, J=8Hz), 7.97(2H, t, J=8Hz), 8.29(1H, d, J=8Hz).

Preparation Example 31-1

In the same manner as in Preparation Example 15-1, 4-chloro-
5 1-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-2-
methylimidazole-5-carbaldehyde was obtained as a yellow oil (440
mg) from 5-chloro-2-methylimidazole-4-carbaldehyde (271 mg) and 3-
chloro-2-chloromethyl-5-(trifluoromethyl)pyridine (474 mg).

¹H-NMR(CDCl₃) : 2.38(3H,s), 5.76(2H, s), 7.97(1H, s), 8.58(1H, s), 9.66(1H, s).

MS (ESI) : m/z 336 (M-1).

Preparation Example 31-2

In the same manner as in Preparation Example 15-2, methyl (E)-3-(4-chloro-1-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-2-methylimidazol-5-yl)-2-propenate was obtained as a yellow oil (342 mg) from 4-chloro-1-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-2-methylimidazole-5-carbaldehyde (430 mg).

¹H-NMR(CDCl₃) : 2.38(3H, s), 2.75(3H, s), 5.39(2H, s), 6.54(1H, d, J=16Hz), 7.34(1H, d, J=16Hz), 8.00(1H, s), 8.66(1H, s).

MS (ESI) : m/z 392 (M-1).

Preparation Example 31-3

In the same manner as in Preparation Example 15-4, (E)-3-(4-chloro-1-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-2-methylimidazol-5-yl)-2-propenic acid (240 mg) was obtained from methyl (E)-3-(4-chloro-1-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-2-methylimidazol-5-yl)-2-propenate (335 mg).

$$^1\text{H-NMR}(\text{DMSO-d}_6) : 2.28(3\text{H}, \text{s}), 5.68(2\text{H}, \text{s}), 6.28(1\text{H}, \text{d}, J=16\text{Hz}), 7.26(1\text{H}, \text{d}, J=16\text{Hz}), 8.60(1\text{H}, \text{s}), 8.89(1\text{H}, \text{s}).$$

30 MS(ESI) : m/z 380(M+1).

Preparation Example 32-1

3-(4-(N,N-bis-(tert-butoxycarbonyl)amino)-2-chlorobenzyl)-5-chloro-2-methylimidazole-4-carbaldehyde (844 mg) was obtained as white amorphous from 5-chloro-2-methylimidazole-4-carbaldehyde (340 mg) and 4-(N,N-bis-(tert-butoxycarbonyl)amino)-2-chlorobenzyl bromide (1.19 g).

$$^1\text{H-NMR}(\text{CDCl}_3) : 1.42(18\text{H}, \text{s}), 2.30(3\text{H}, \text{s}), 5.65(2\text{H}, \text{s}), 6.52(1\text{H}, \text{d}, J=8\text{Hz}), 6.99(1\text{H}, \text{dd}, J=8, 2\text{Hz}), 7.26(1\text{H}, \text{d}, J=2\text{Hz}), 9.76(1\text{H}, \text{s}).$$

Preparation Example 32-2

40 Methyl (E)-3-(1-(4-(N,N-bis-(tert-butoxycarbonyl)amino)-2-

g) as a pale-yellow solid.

$^1\text{H-NMR}$ (CDCl_3) : 1.32 (3H, t, $J=6\text{Hz}$), 2.75 (2H, q, $J=6\text{Hz}$), 6.89 (1H, s).

MS (ESI) : m/z 176 ($M+1$)

5 Preparation Example 33-2

4-Bromo-2-ethylimidazole (24.4 g) was dissolved in ethanol (244 ml), and 1N aqueous sodium hydroxide solution (105 ml) and 37% formalin (15.6 ml) were added. The mixture was stirred at room temperature for 15 hr. The reaction mixture was neutralized under ice-cooling and concentrated to dryness under reduced pressure. The residue was extracted with chloroform-methanol (4/1) and insoluble matter was filtered off. The residue was concentrated to dryness under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol=49:1-19:1) to give 4-bromo-2-ethyl-5-(hydroxymethyl)imidazole (18.9 g) as a yellow powder.

$^1\text{H-NMR}$ ($\text{DMSO}-d_6$) : 1.16 (3H, t, $J=6\text{Hz}$), 2.55 (2H, q, $J=6\text{Hz}$), 4.30 (2H, d, $J=4\text{Hz}$), 5.14 (1H, t, $J=4\text{Hz}$).

Preparation Example 33-3

4-Bromo-2-ethyl-5-(hydroxymethyl)imidazole (18.9 g) was dissolved in dry dimethylformamide (189 ml), and manganese dioxide (80.1 g) was added. The mixture was stirred at room temperature for 5 hr and left standing overnight. The reaction mixture was filtered through celite and insoluble matter was washed with chloroform. The filtrate and washing were combined and concentrated to dryness under reduced pressure. The residue was washed with water to give 5-bromo-2-ethylimidazole-4-carbaldehyde (12.9 g) as a brown powder.

$^1\text{H-NMR}$ (CDCl_3) : 1.37 (3H, t, $J=6\text{Hz}$), 2.86 (2H, q, $J=6\text{Hz}$), 9.58 (1H, s).

30 Preparation Example 33-4

In the same manner as in Preparation Example 1-4, 5-chloro-2-ethylimidazole-4-carbaldehyde was obtained as orange crystals (6.6 g) from 5-bromo-2-ethylimidazole-4-carbaldehyde (12 g).

$^1\text{H-NMR}$ ($\text{DMSO}-d_6$) : 1.20 (3H, t, $J=7\text{Hz}$), 2.66 (2H, q, $J=7\text{Hz}$), 9.59 (1H, s).

MASS (ESI) : m/z 157 ($M-1$).

Preparation Example 33-5

In the same manner as in Preparation Example 15-1, 4-chloro-1-(2-chloro-4-(n-pentyloxy)benzyl)-2-ethylimidazole-5-carbaldehyde was obtained as a pale-yellow oil (260 mg) from 5-chloro-2-

MASS(ESI) : m/z 363(M+1).

Preparation Example 34-2

In the same manner as in Preparation Example 15-2, methyl (E)-3-(1-(4-bromo-2-chlorobenzyl)-4-chloro-2-ethylimidazol-5-yl)-2-propenate was obtained as a colorless solid (1.06 g) from 1-(4-bromo-2-chlorobenzyl)-4-chloro-2-ethylimidazole-5-carbaldehyde (1.0 g) and methyl (triphenylphosphoranylidene)acetate (1.39 g).
¹H-NMR(CDCl₃) : 1.28(3H, t, J=7Hz), 2.59(2H, q, J=7Hz), 3.75(3H, s), 5.16(2H, s), 6.32(1H, d, J=8Hz), 6.50(1H, d, J=15Hz), 7.29(1H, d, J=15Hz), 7.34(1H, dd, J=8, 1Hz), 7.63(1H, d, J=1Hz).
MASS(ESI) : m/z 419(M+1).

Preparation Example 34-3

In the same manner as in Preparation Example 15-4, (E)-3-(1-(4-bromo-2-chlorobenzyl)-4-chloro-2-ethylimidazol-5-yl)-2-propenic acid was obtained as a colorless solid (228 mg) from methyl (E)-3-(1-(4-bromo-2-chlorobenzyl)-4-chloro-2-ethylimidazol-5-yl)-2-propenate (260 mg).
¹H-NMR(DMSO-d₆) : 1.14(3H, t, J=7Hz), 2.65(2H, q, J=7Hz), 5.38(2H, s), 6.36(1H, d, J=15Hz), 6.43(1H, d, J=8Hz), 7.20(1H, d, J=15Hz), 7.52(1H, dd, J=8, 1Hz), 7.87(1H, d, J=1Hz).
MASS(ESI) : m/z 403(M+1).

Preparation Example 35-1

In the same manner as in Preparation Example 15-1, 4-chloro-1-(2-chloro-4-iodobenzyl)-2-ethylimidazole-4-carbaldehyde was obtained as a pale-yellow gum (2.68 g) from 5-chloro-2-ethylimidazole-4-carbaldehyde (1.2 g) and 2-chloro-4-iodobenzyl bromide (3.76 g).
¹H-NMR(CDCl₃) : 1.28(3H, t, J=7Hz), 2.58(2H, q, J=7Hz), 5.56(2H, s), 6.20(1H, d, J=8Hz), 7.50(1H, dd, J=8, 1Hz), 7.78(1H, d, J=1Hz), 9.75(1H, s).
MASS(ESI) : m/z 409(M+1).

Preparation Example 35-2

In the same manner as in Preparation Example 15-2, methyl (E)-3-(4-chloro-1-(2-chloro-4-iodobenzyl)-2-ethylimidazol-5-yl)-2-propenate was obtained as pale-yellow crystals (2.53 g) from 4-chloro-1-(2-chloro-4-iodobenzyl)-2-ethylimidazole-5-carbaldehyde (2.65 g) and methyl (triphenylphosphoranylidene)acetate (3.25 g).
¹H-NMR(CDCl₃) : 1.28(3H, t, J=7Hz), 2.59(2H, q, J=7Hz), 3.75(3H, s), 5.15(2H, s), 6.16(1H, d, J=8Hz), 6.49(1H, d, J=15Hz), 7.27(1H, d, J=15Hz), 7.51(1H, dd, J=8, 1Hz), 7.81(1H, d, J=1Hz).

MASS (ESI) : m/z 465 (M+1).

Preparation Example 35-3

In the same manner as in Preparation Example 17-1, methyl (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-2-propenic acid was obtained as gray crystals (522 mg) from methyl (E)-3-(4-chloro-1-(2-chloro-4-iodobenzyl)-2-ethylimidazol-5-yl)-2-propenate (600 mg) and phenylacetylene (439 mg).

¹H-NMR(CDCl₃) : 1.28(3H, t, J=7Hz), 2.62(2H, q, J=7Hz), 3.75(3H, s), 5.23(2H, s), 6.44(1H, d, J=8Hz), 6.50(1H, d, J=15Hz), 7.28-7.40(4H, m), 7.47-7.55(2H, m), 7.63(1H, d, J=1Hz).

MASS (ESI) : m/z 439 (M+1) .

Preparation Example 35-4

In the same manner as in Preparation Example 15-4, (E)-3-(4-chloro-1-(2-chloro-4-(phenylacetyl)benzyl)-2-ethylimidazol-5-yl)-2-propenic acid was obtained as gray crystals (410 mg) from methyl (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-ethylimidazol-5-yl)-2-propenate (500 mg).

¹H-NMR(DMSO-d₆) : 1.15(3H, t, J=7Hz), 2.67(2H, q, J=7Hz), 5.46(2H, s), 6.27(1H, d, J=15Hz), 6.54(1H, d, J=8Hz), 7.23(1H, d, J=15Hz), 7.40-7.60(6H, m), 7.79(1H, d, J=1Hz).

MASS (ESI) : m/z 423 (M-1) .

Preparation Example 36-1

A suspension of methyl (E)-3-(4-chloro-1-(2-chloro-4-iodobenzyl)-2-ethylimidazol-5-yl)-2-propenate (600 mg), palladium acetate (600 mg) and tri-*o*-tolylphosphine (39 mg) in anhydrous triethylamine (5.4 ml) was stirred at room temperature in a nitrogen atmosphere. Ten min. later, styrene (672 mg) was added and the reaction mixture was heated to 100°C. After heating for 2 hr, the mixture was ice-cooled. Water was added and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and filtrated. The filtrate was concentrated, and the residue was applied to flash silica gel chromatography (silica gel, 150 ml). Elution with hexane:ethyl acetate=10:1 - 7:1 - 5:1 - 4:1 gave a pale-yellow gum (435 mg). This was crystallized from isopropyl ether to give methyl (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-ethylimidazol-5-yl)-2-propenate as pale-yellow crystals (405 mg).

40 $^1\text{H-NMR}$ (CDCl_3) : 1.29 (3H, t, $J=7\text{Hz}$), 2.63 (2H, q, $J=7\text{Hz}$), 3.74 (3H, s),

姓名	性别	出生年月	籍贯	民族	文化程度	政治面貌	工作单位	职务	备注
王德胜	男	1945.12	山东烟台	汉族	高中	中共党员	烟台市公安局	科长	
李国强	男	1950.08	河南郑州	汉族	大学	中共党员	河南省公安厅	处长	
张为民	男	1955.03	江苏苏州	汉族	大学	中共党员	江苏省公安厅	处长	
赵子龙	男	1960.01	四川成都	汉族	大学	中共党员	四川省公安厅	处长	
周树人	男	1965.05	浙江杭州	汉族	大学	中共党员	浙江省公安厅	处长	
吴永年	男	1970.09	广东广州	汉族	大学	中共党员	广东省公安厅	处长	
陈永年	男	1975.12	福建福州	汉族	大学	中共党员	福建省公安厅	处长	
林永年	男	1980.06	江西九江	汉族	大学	中共党员	江西省公安厅	处长	
孙永年	男	1985.10	湖南长沙	汉族	大学	中共党员	湖南省公安厅	处长	
周永年	男	1990.04	湖北武汉	汉族	大学	中共党员	湖北省公安厅	处长	
吴永年	男	1995.08	安徽合肥	汉族	大学	中共党员	安徽省公安厅	处长	
陈永年	男	2000.12	浙江杭州	汉族	大学	中共党员	浙江省公安厅	处长	
林永年	男	2005.06	江西九江	汉族	大学	中共党员	江西省公安厅	处长	
孙永年	男	2010.10	湖南长沙	汉族	大学	中共党员	湖南省公安厅	处长	
周永年	男	2015.04	湖北武汉	汉族	大学	中共党员	湖北省公安厅	处长	
吴永年	男	2020.08	安徽合肥	汉族	大学	中共党员	安徽省公安厅	处长	
陈永年	男	2025.12	浙江杭州	汉族	大学	中共党员	浙江省公安厅	处长	

10 7.37–7.70 (2H, m)

15 3-(1-(4-bromo-2-chlorobenzyl)-2,4-dimethylimidazol-5-yl)-2-

20 Preparation Example 38-1

$$^1\text{H-NMR}(\text{CDCl}_3) : 0.92(3\text{H}, \text{t}, J=7\text{Hz}), 1.30-1.45(4\text{H}, \text{m}), 1.70-1.80(2\text{H}, \text{m}), 2.33(3\text{H}, \text{s}), 3.90(2\text{H}, \text{t}, J=7\text{Hz}), 5.58(2\text{H}, \text{s}), 6.44(1\text{H}, \text{d}, J=8\text{Hz}), 6.70(1\text{H}, \text{dd}, J=8, 2\text{Hz}), 6.95(1\text{H}, \text{d}, J=2\text{Hz}), 9.71(1\text{H}, \text{s})$$

30 In the same manner as in Preparation Example 15-2, methyl
(E)-3-(4-bromo-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-
methylimidazol-5-yl)-2-propenate (488 mg) was obtained as
colorless crystals from 4-bromo-1-(2-chloro-4-(1-
pentyloxy)benzyl)-2-methyl-1H-imidazole-5-carbaldehyde (479 mg)
35 and methyl (triphenylphosphoranylidene)acetate (481 mg).

53

Preparation Example 38-3

In the same manner as in Preparation Example 15-4, (E)-3-(4-bromo-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (447 mg) was obtained as a colorless powder from
 5 methyl (E)-3-(4-bromo-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-propenate (462 mg).

¹H-NMR (DMSO-d₆) : 0.88 (3H, t, J=7Hz), 1.25-1.42 (4H, m), 1.62-1.72 (2H, m), 2.33 (3H, s), 3.96 (2H, t, J=7Hz), 5.31 (2H, s), 6.29 (1H, d, J=15Hz), 6.42 (1H, d, J=8Hz), 6.88 (1H, dd, J =8, 2Hz), 7.13 (1H,
 10 d, J=2Hz), 7.22 (1H, d, J=15Hz)

Preparation Example 39-1

Lithium chloride (180 mg) was suspended in 1,4-dioxane (10 ml), and 4-bromo-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-1H-imidazole-5-carbaldehyde (707 mg), vinyltributyltin (617 mg) and
 15 tetrakis(triphenylphosphine)palladium(0) (102 mg) were added. The mixture was refluxed under heating for 12 hr. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced
 20 pressure. The residue was applied to silica gel column chromatography and eluted with hexane/ethyl acetate=5/1. The objective fraction was concentrated under reduced pressure to give 1-(2-chloro-4-(1-pentyloxy)benzyl)-4-ethenyl-2-methyl-1H-imidazole-5-carbaldehyde (538 mg) as a pale-yellow gum.

¹H-NMR (CDCl₃) : 0.92 (3H, t, J=7Hz), 1.30-1.47 (4H, m), 1.70-1.80 (2H, m), 2.34 (3H, s), 3.90 (2H, t, J=7Hz), 5.54 (1H, dd, J=8, 2Hz), 5.56 (2H, s), 6.26 (1H, dd, J=15, 2Hz), 6.40 (1H, d, J=8Hz), 6.67 (1H, dd, J=8, 2Hz), 6.95-7.05 (2H, m), 9.90 (1H, s)

Preparation Example 39-2

30 1-(2-Chloro-4-(1-pentyloxy)benzyl)-4-ethenyl-2-methyl-1H-imidazole-5-carbaldehyde (575 mg) was dissolved in 1,4-dioxane (6 ml) and palladium carbon (50 mg) was added. The mixture was stirred under a hydrogen atmosphere for 1.5 hr. The reaction mixture was filtered through celite. Water was added to the
 35 filtrate and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was applied to silica gel column chromatography and eluted with chloroform/ethyl acetate=2/1. The objective fraction was concentrated under
 40 reduced pressure to give 1-(2-chloro-4-(1-pentyloxy)benzyl)-4-

applied to silica gel column chromatography and eluted with hexane/ethyl acetate=1/2. The objective fraction was concentrated under reduced pressure to give 1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-1H-imidazole-5-carbaldehyde (3.10 g) as a pale-yellow oil.

¹H-NMR(CDCl₃) : 0.92(3H, t, J=7Hz), 1.33-1.47(4H, m), 1.72-1.82(2H, m), 2.35(3H, s), 3.90(2H, t, J=7Hz), 5.59(2H, s), 6.37(1H, d, J=8Hz), 6.67(1H, dd, J=8, 2Hz), 6.95(1H, d, J=2Hz), 7.78(1H, s), 9.68(1H, s)

Preparation Example 40-2

10 In the same manner as in Preparation Example 42-1 to be
mentioned later, a crude purified product of ethyl 2-benzyl-3-(1-
(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-3-
hydroxypropanate was obtained as a brown oil from 1-(2-chloro-4-
(1-pentyloxy)benzyl)-2-methyl-1H-imidazole-5-carbaldehyde (500 mg)
15 and ethyl 3-phenyl propionate (361 mg).

Preparation Example 40-3

In the same manner as in Preparation Example 42-2 to be mentioned later, ethyl (E)-2-benzyl-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-propenate (405 mg) was
20 obtained as a pale-yellow oil from the crude purified product of ethyl 2-benzyl-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-3-hydroxypropanate.

¹H-NMR(CDCl₃) : 0.93(3H, t, J=7Hz), 1.19(3H, t, J=7Hz), 1.32-1.47(4H, m), 1.70-1.82(2H, m), 2.36(3H, s), 3.92(2H, t, J=7Hz), 3.97(2H, s), 4.14(2H, q, J=7Hz), 5.17(2H, s), 6.32(1H, d, J=8Hz), 6.69(1H, dd, J=8, 2Hz), 6.98(1H, d, J=2Hz), 7.13-7.28(6H, m), 7.46(1H, s)

Preparation Example 40-4

In the same manner as in Preparation Example 15-4, (E)-2-
30 benzyl-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-
yl)-2-propenic acid (308 mg) was obtained as a pale-yellow powder
from ethyl (E)-2-benzyl-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-
methylimidazol-5-yl)-2-propenate (385 mg).

¹H-NMR(DMSO-d₆) : 0.88(3H, t, J=7Hz), 1.27-1.43(4H, m), 1.65-1.74(2H, m), 2.29(3H, s), 3.86(2H, s), 3.96(2H, t, J=7Hz), 5.26(2H, s), 6.31(1H, d, J=8Hz), 6.85(1H, dd, J=8, 2Hz), 7.07-7.30(7H, m), 7.43(1H, s)

Preparation Example 41-1

In the same manner as in Preparation Example 42-1, a crude
40 purified product of ethyl 3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-

methylimidazol-5-yl)-3-hydroxy-2-(1-pentyl)propanate was obtained as a brown oil from 1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-1H-imidazole-5-carbaldehyde (500 mg) and ethyl n-heptanate (321 mg).

5 Preparation Example 41-2

In the same manner as in Preparation Example 42-2, ethyl (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-(1-pentyl)-2-propenoate (425 mg) was obtained as a pale-yellow oil from the crude purified product of ethyl 3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-3-hydroxy-2-(1-pentyl)propanoate.

¹H-NMR(CDCl₃) : 0.87-0.94(6H, m), 1.27(3H, t, J=7Hz), 1.32-1.55(10H, m), 1.72-1.82(2H, m), 2.37(3H, s), 2.54(2H, t, J=7Hz), 3.90(2H, t, J=7Hz), 4.18(2H, q, J=7Hz), 5.14(2H, s), 6.31(1H, d, J=8Hz),
15 6.67(1H, dd, J=8, 2Hz), 6.96(1H, d, J=2Hz), 7.19(1H, s), 7.31(1H, s)

Preparation Example 41-3

In the same manner as in Preparation Example 15-4, (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-(1-pentyl)-2-propenic acid (305 mg) was obtained as a pale-yellow powder from ethyl (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-(1-pentyl)-2-propenate (405 mg).

¹H-NMR(DMSO-d₆) : 0.85-0.87(6H, m), 1.20-1.38(10H, m), 1.62-1.72(2H, m), 2.30(3H, s), 2.42(2H, t, J=7Hz), 3.94(2H, t, J=7Hz), 5.21(2H, s), 6.28(1H, d, J=8Hz), 6.85(1H, dd, J=8, 2Hz), 7.10(1H, d, J=2Hz), 7.13(1H, s), 7.22(1H, s)

Preparation Example 42-1

Diisopropylamine (237 mg) was dissolved in tetrahydrofuran (3 ml), and a solution (1.53 ml) of 1.53M n-butyl lithium in
30 hexane was added under a nitrogen atmosphere while cooling on a dry ice - acetone bath. The mixture was stirred on an ice water bath and a solution of methyl 3-(3-pyridyl)propionate (335 mg) in tetrahydrofuran (1 ml) was added while cooling on a dry ice - acetone bath. The mixture was stirred on a dry ice - acetone bath
35 for 1 hr and a solution of 1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-1H-imidazole-5-carbaldehyde (500 mg) in tetrahydrofuran (1 ml) was added. The mixture was stirred on a dry ice - acetone bath for 1 hr and saturated aqueous ammonium chloride solution was added. The mixture was extracted with ethyl acetate, and the
40 organic layer was washed with saturated brine, dried by the

to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To the residue was added hexane (10 ml) and the precipitated crystals were collected by filtration and dried by heating under reduced pressure to give 4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-5-hydroxymethyl-2-methyl-1H-imidazole (786 mg) as colorless crystals.

¹H-NMR(CDCl₃) : 0.93(3H, t, J=7Hz), 1.30-1.48(4H, m), 1.72-1.85(2H, m), 2.26(3H, s), 3.91(2H, t, J=7Hz), 4.50(2H, s), 5.18(2H, s), 6.40(1H, d, J=8Hz), 6.70(1H, dd, J=8, 2Hz), 6.96(1H, d, J=2Hz)

Preparation Example 47-1

In the same manner as in Preparation Example 9, 4-chloro-5-chloromethyl-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-1H-imidazole (707 mg) was obtained as a brown oil from 4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-5-hydroxymethyl-2-methyl-1H-imidazole (611 mg).

¹H-NMR(CDCl₃) : 0.93(3H, t, J=7Hz), 1.32-1.48(4H, m), 1.73-1.82(2H, m), 2.33(3H, s), 3.92(2H, t, J=7Hz), 4.48(2H, s), 5.17(2H, s), 6.46(1H, d, J=8Hz), 6.73(1H, dd, J=8, 2Hz), 6.97(1H, d, J=2Hz)

Preparation Example 47-2

A solution of 4-chloro-5-chloromethyl-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-1H-imidazole (340 mg) in acetonitrile (3 ml) was added gradually to a mixed solvent of 28% aqueous ammonia (6 ml) and acetonitrile (6 ml) under ice-cooling. The reaction mixture was stirred at room temperature for 1 hr. Saturated aqueous sodium hydrogencarbonate solution was added and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was applied to silica gel column chromatography and eluted with chloroform/methanol=100/1. The objective fraction was concentrated under reduced pressure to give 5-aminomethyl-4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-1H-imidazole (82 mg) as a pale-brown oil.

¹H-NMR(CDCl₃) : 0.93(3H, t, J=7Hz), 1.32-1.48(4H, m), 1.73-1.83(2H, m), 2.26(3H, s), 3.70(2H, s), 3.91(2H, t, J=7Hz), 5.19(2H, s), 6.37(1H, d, J=8Hz), 6.70(1H, dd, J=8, 2Hz), 6.96(1H, d, J=2Hz)

Preparation Example 48

In the same manner as in Preparation Example 47-2, 5-(N-

4-Bromo-2-ethyl-1-(methoxymethyl)imidazole-5-carbaldehyde (365 g) was dissolved in 35% conc. hydrochloric acid (1.8 L), and the mixture was heated at 90°C for 20 hr. The solvent was evaporated under reduced pressure, and sodium hydrogencarbonate was added to the residue under ice-cooling until the mixture assumed weak alkalinity. The mixture was extracted with chloroform, and the organic layer was dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure and diisopropyl ether was added to the residue. The mixture was heated and allowed to cool. The precipitated crystals were collected by filtration and dried by heating under reduced pressure to give 4-chloro-2-ethylimidazole-5-carbaldehyde (211.5 g) as brown crystals.

¹H-NMR(CDCl₃) : 1.37(3H, t, J=7Hz), 2.85(2 H, q, J=7Hz), 9.63(1H, s), 11.30(1H, brs)

Example 1

To a suspension of (E)-3-(4-chloro-1-(2-chloro-4-(2-furyl)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (155 mg) in N,N-dimethylformamide (0.8 ml) was added 1,1'-carbonyldiimidazole (101 mg) at room temperature, and the mixture was stirred for 1 hr. Thereto were added (4-methylbenzene)sulfonamide (106 mg) and 1,8-diazabicyclo[5.4.0]-7-undecene (96 mg), and the mixture was stirred at 50°C for 5 hr. The reaction mixture was ice-cooled and 1N hydrochloric acid (1.7 ml) was added dropwise to neutralize the solution. Water (4 ml) was added and the precipitate was collected by filtration. This crude product was recrystallized from acetone - water to give (E)-3-(4-chloro-1-(2-chloro-4-(2-furyl)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide (152 mg) as a pale-yellow powder.

¹H-NMR(CDCl₃) : 2.34(3H, s), 2.40(3H, s), 5.17(2H, s), 6.38(1H, d, J=8Hz), 6.49(1H, dd, J=3 and 2Hz), 6.53(1H, d, J=16Hz), 6.68(1H, d, J=3Hz), 7.31(2H, d, J=8Hz), 7.35(1H, d, J=16Hz), 7.43(1H, dd, J=8 and 2Hz), 7.49(1H, d, J=2Hz), 7.74(1H, d, J=2Hz), 7.92(2H, d, J=8Hz).

Mass(ESI) : m/e 528 (M-H)-.
m.p. 242-243°C.

Example 2

In the same manner as in Example 1, (2E)-3-(4-chloro-1-(2-chloro-4-(2-furyl)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide (159 mg) was obtained as a

(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (130 mg) and (4-methylbenzene)sulfonamide (81 mg).

¹H-NMR(CDCl₃) : 2.32(3H, s), 2.41(3H, s), 5.17(2H, s), 6.34(1H, d, J=8Hz), 6.56(1H, d, J=16Hz), 7.27-7.40(7H, m), 7.48-7.55(2H, m),
5 7.60(1H, d, J=2Hz), 7.93(2H, d, J=8Hz).

Mass(ESI) : m/z 562(M-1).

m.p. 239-241°C.

Example 6

In the same manner as in Example 1, (2E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide was obtained as thin other crystals (101 mg) from (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (130 mg) and (E)-(2-phenylethene)sulfonamide (87 mg).

15 ¹H-NMR(CDCl₃) : 2.34(3H, s), 5.20(2H, s), 6.39(1H, d, J=8Hz), 6.61(1H, d, J=16Hz), 7.05(1H, d, J=16Hz), 7.30(1H, dd, J=2, 8Hz), 7.33-7.44(7H, m), 7.46-7.55(4H, m), 7.60(1H, d, J=2Hz), 7.71(1H, d, J=16Hz).

Mass(ESI) : m/z 574(M-1).

20 m.p. 220-222°C.

Example 7

In the same manner as in Example 1, (E)-3-(1-(4-bromo-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide (162 mg) was obtained as
25 colorless crystals from (E)-3-(1-(4-bromo-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-2-propenic acid (150 mg) and (4-methylbenzene)sulfonamide (99 mg).

¹H-NMR(CDCl₃) : 2.31(3H, s), 2.43(3H, s), 5.10(2H, s), 6.23(1H, d, J=8Hz), 6.58(1H, d, J=15Hz), 7.25-7.33(4H, m), 7.58(1H, d, J=2Hz),
30 7.92(2H, d, J=8Hz).

Mass(ESI) : m/z 542(M-H)-.

m.p. 233-235°C.

Example 8

In the same manner as in Example 1, (E)-3-(1-(4-bromo-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide (172 mg) was obtained as
35 colorless crystals from (E)-3-(1-(4-bromo-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-2-propenic acid (168 mg) and (E)-(2-phenylethene)sulfonamide (118 mg).

40 ¹H-NMR(CDCl₃-CD₃OD) : 2.32(3H, s), 5.15(2H, s), 6.28(1H, d, J=8Hz),

6.70(1H, d, J=15Hz), 7.08(1H, d, J=15Hz), 7.31-7.42(5H, m), 7.49-7.53(2H, m), 7.62(1H, d, J=2Hz), 7.69(1H, d, J=15Hz).

Mass(ESI) : m/z 554(M-H)-.

m.p. 250-251°C.

5 Example 9

In the same manner as in Example 1, (E)-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-N-(1-pentanesulfonyl)-2-propenamide (134 mg) was obtained as colorless crystals from (E)-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-2-propenic acid (150 mg).

¹H-NMR(CDCl₃) : 0.87(3H, t, J=8Hz), 1.24-1.45(4H, m), 1.75-1.89(2H, m), 2.40(3H, s), 3.38-3.47(2H, m), 5.26(2H, s), 6.50 (1H, d, J=8Hz), 6.57(1H, d, J=15Hz), 7.35-7.58(7H, m), 7.68(1H, d, J=2Hz), 8.18(1H, br s).

15 Mass(ESI) : m/z 520(M+1).

m.p. 203-204°C.

Example 10

In the same manner as in Example 1, (E)-N-benzenesulfonyl-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-2-propenamide (141 mg) was obtained as colorless crystals from (E)-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-2-propenic acid (150 mg).

¹H-NMR(CDCl₃) : 2.36(3H, s), 5.20(2H, s), 6.43(1H, d, J=8Hz), 6.57(1H, d, J=15Hz), 7.31-7.55(9H, m), 7.59(1H, d, J=8Hz), 7.64(1H, d, J=2Hz), 8.05(2H, d, J=8Hz), 8.54(1H, br s).

25 Mass(ESI) : m /z 526(M+1).

m.p. 245-247°C.

Example 11

In the same manner as in Example 1, (E)-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-N-((4-methylbenzene)sulfonyl)-2-propenamide (137 mg) was obtained as colorless crystals from (E)-3-[4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl]-2-propenic acid (150 mg).

¹H-NMR(CDCl₃) : 2.35(3H, s), 2.40(3H, s), 5.19(2H, s), 6.43(1H, d, J=8Hz), 6.57(1H, d, J=15Hz), 7.24-7.55(8H, m), 7.65(1H, d, J=1Hz), 7.92(2H, d, J=8Hz), 8.41(1H, br s).

35 Mass(ESI) : m/z 540(M+1).

m.p. 229-232°C.

Example 12

40 In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-

chloro-4-phenylbenzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide (132 mg) was obtained as colorless crystals from (E)-3-(4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl)-2-propenic acid (150 mg) and (E)-(2-phenylethene)sulfonamide (106 mg).

¹H-NMR(CDCl₃) : 2.37(3H, s), 5.22(2H, s), 6.47(1H, d, J=8Hz), 6.57(1H, d, J=15Hz), 7.03(1H, d, J=15Hz), 7.37-7.54(12H, m), 7.65(1H, s), 7.71(1H, d, J=15Hz).

Mass (ESI) : m/z 554 (M+H) +.

10 m.p. 240-241°C.

Example 13

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl)-N-((5-chloro-2-thienyl)sulfonyl)-2-propenamide (126 mg) was obtained as colorless
15 crystals from (E)-3-(4-chloro-1-(2-chloro-4-phenylbenzyl)-2-methylimidazol-5-yl)-2-propenic acid (150 mg) and 5-chlorothiophene-2-sulfonamide (115 mg).

¹H-NMR(CDCl₃) : 2.37(3H, s), 5.21(2H, s), 6.46(1H, d, J=8Hz),
6.60(1H, d, J=15Hz), 6.90(1H, d, J=4Hz), 7.37-7.53(7H, m), 7.64-
20 7.66(2H, m).

Mass (ESI) : m/z 566 (M+H) +.

m.p. 229–233°C.

Example 14

In the same manner as in Example 1, (E)-N-((5-bromo-2-
25 thienyl)sulfonyl)-3-(4-chloro-1-(2-chloro-4-phenylbenzyl)-2-
methylimidazol-5-yl)-2-propenamide (155 mg) was obtained as
colorless crystals from (E)-3-(4-chloro-1-(2-chloro-4-
phenylbenzyl)-2-methylimidazol-5-yl)-2-propenic acid (150 mg) and
5-bromothiophene-2-sulfonamide (141 mg).

¹H-NMR(CDCl₃) : 2.37(3H, s), 5.21(2H, s), 6.46(1H, d, J=8Hz), 6.59(1H, d, J=15Hz), 7.04(1H, d, J=4Hz), 7.36-7.55(7H, m), 7.61(1H, d, J=4Hz), 7.66(1H, d, J=2Hz).

Mass (ESI) : m/z 612 (M+H)+.

m.p. 234–235°C.

35 Example 15

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-(1-propoxy)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide (155 mg) was obtained as colorless crystals from (E)-3-(4-chloro-1-(2-chloro-4-(1-
40 propoxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (145 mg)

and (4-methylbenzene)sulfonamide (96 mg).

¹H-NMR(CDCl₃-CD₃OD) : 1.02(3H, t, J=7Hz), 1.73-1.85(2H, m), 2.30(3H, s), 2.41(3H, s), 3.88(2H, t, J=7Hz), 5.10(2H, s), 6.27(1H, d, J=8Hz), 6.64(1H, d, J=15Hz), 6.68(1H, dd, J=8, 2Hz), 6.97(1H, d, J=2Hz), 7.27-7.33(3H, m), 7.92(2H, d, J=8Hz).

Mass (ESI) : m/z 520 (M-H)-.

m.p. 226-228°C.

Example 16

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-(1-propoxy)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide (164 mg) was obtained as colorless crystals from (E)-3-(4-chloro-1-(2-chloro-4-(1-propoxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (143 mg) and (E)-(2-phenylethene)sulfonamide (106 mg).

¹H-NMR(CDCl₃-CD₃OD) : 1.02(3H, t, J=7Hz), 1.73-1.85(2H, m), 2.32(3H, s), 3.88(2H, t, J=7Hz), 5.15(2H, s), 6.33(1H, d, J=8Hz), 6.69(1H, d, J=15Hz), 6.70(1H, dd, J=8, 2Hz), 6.98(1H, d, J=2Hz), 7.09(1H, d, J=15Hz), 7.35-7.42(4H, m), 7.50-7.54(2H, m), 7.68(1H, d, J=15Hz).

Mass (ESI) : m/z 532 (M-H)-.

m.p. 199-201°C.

Example 17

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide was obtained as colorless crystals (60 mg) from (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (100 mg) and (4-methylbenzene)sulfonamide (65 mg).

¹H-NMR(CDCl₃) : 0.93(3H, t, J=7Hz), 1.30-1.50(4H, m), 1.70-1.84(2H, m), 2.32(3H, s), 2.42(3H, s), 3.90(2H, t, J=7Hz), 5.09(2H, s), 6.27(1H, d, J=8Hz), 6.53(1H, d, J=16Hz), 6.67(1H, dd, J=2, 8Hz), 6.96(1H, d, J=2Hz), 7.28-7.39(3H, m), 7.93(2H, d, J=8Hz).

Mass (ESI) : m/z 548 (M-1).

m.p. 195-197°C.

Example 18

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide was obtained as colorless crystals (84 mg) from (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (100 mg) and (E)-(2-phenylethene)sulfonamide (69 mg).

¹H-NMR(CDCl₃) : 0.92(3H, t, J=7Hz), 1.30-1.49(4H, m), 1.69-1.72(2H, m), 2.34(3H, s), 3.90(2H, t, J=7Hz), 5.13(2H, s), 6.32(1H, d, J=8Hz), 6.56(1H, d, J=16Hz), 6.68(1H, dd, J=2, 8Hz), 6.96(1H, d, J=2Hz), 7.06(1H, d, J=16Hz), 7.35-7.56(6H, m), 7.72(1H, d, J=16Hz).
 5 Mass(ESI) : m/z 560(M-1).
 m.p. 196-199°C.

Example 19

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-((cyclopentyl)methoxy)benzyl)-2-methylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide (82 mg) was obtained as a white powder from (E)-3-(4-chloro-1-(2-chloro-4-((cyclopentyl)-methoxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (164 mg) and 1-pentanesulfonamide (90 mg).

¹H-NMR(CDCl₃) : 0.90(3H, t, J=7Hz), 1.25-1.92(14H, m), 2.34(1H, sept, J=7Hz), 2.37(3H, s), 3.38-3.50(2H, m), 3.80(2H, d, J=7Hz), 5.16(2H, s), 6.34(1H, d, J=8Hz), 6.51(1H, d, J=15Hz), 6.72(1H, dd, J=8 and 2Hz), 7.00(1H, d, J=2Hz), 7.44(1H, d, J=16Hz).
 Mass(ESI) : m/e 540 (M-H)-.
 m.p. 177-178°C.

20 Example 20

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-((cyclopentyl)methoxy)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide (135 mg) was obtained as a white powder from (E)-3-(4-chloro-1-(2-chloro-4-((cyclopentyl)-methoxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (163 mg) and (4-methylbenzene)sulfonamide (106 mg).

¹H-NMR(CDCl₃) : 1.25-1.92(8H, m), 2.32(3H, s), 2.33(1H, sept, J=7Hz), 2.42(3H, s), 3.78(2H, d, J=7Hz), 5.09(2H, s), 6.27(1H, d, J=8Hz), 6.52(1H, d, J=16Hz), 6.68(1H, dd, J=8 and 2Hz), 6.97(1H, d, J=2Hz), 7.32(2H, d, J=8Hz), 7.34(1H, d, J=16Hz), 7.94(2H, d, J=8Hz).
 Mass(ESI) : m/e 560(M-H)-.
 m.p. 217-218°C.

Example 21

In the same manner as in Example 1, (2E)-3-(4-chloro-1-(2-chloro-4-((cyclopentyl)methoxy)benzyl)-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide (128 mg) was obtained as a white powder from (E)-3-(4-chloro-1-(2-chloro-4-((cyclopentyl)methoxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (164 mg) and (E)-(2-phenylethene)sulfonamide (99 mg).

¹H-NMR(CDCl₃) : 1.23-1.92(8H, m), 2.32(1H, sept, J=7Hz), 2.33(3H, s), 3.77(2H, d, J=7Hz), 5.12(2H, s), 6.32(1H, d, J=8Hz), 6.60(1H, d, J=16Hz), 6.68(1H, dd, J=8 and 2Hz), 6.96(1H, d, J=2Hz), 7.08(1H, d, J=16Hz), 7.33-7.56(5H, m), 7.40(1H, d, J=16Hz), 7.70(1H, d, J=16Hz).

Mass(ESI) : m/e 572 (M-H)-.

m.p. 200-201°C.

Example 22

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-((cyclohexyl)methyloxy)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide was obtained as colorless crystals (61 mg) from (E)-3-(4-chloro-1-(2-chloro-4-((cyclohexyl)methyloxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (85 mg) and (4-methylbenzene)sulfonamide (52 mg).

¹H-NMR(CDCl₃) : 0.95-1.89(11H, m), 2.32(3H, s), 2.42(3H, s), 3.70(2H, d, J=7Hz), 5.10(2H, s), 6.22(1H, d, J=8Hz), 6.50(1H, d, J=16Hz), 6.67(1H, dd, J=2, 8Hz), 6.97(1H, d, J=2Hz), 7.30-7.38(3H, m), 7.94(2H, d, J=8Hz).

Mass(ESI) : m/z 574 (M-1).

m.p. 214-216°C.

Example 23

In the same manner as in Example 1, (2E)-3-(4-chloro-1-(2-chloro-4-((cyclohexyl)methyloxy)benzyl)-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide was obtained as colorless crystals (63 mg) from (E)-3-(4-chloro-1-(2-chloro-4-((cyclohexyl)methyloxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (85 mg) and (E)-(2-phenylethene)sulfonamide (55 mg).

¹H-NMR(CDCl₃) : 0.95-1.37(6H, m), 1.65-1.88(5H, m), 2.35(3H, s), 3.70(2H, d, J=7Hz), 5.13(2H, s), 6.31(1H, d, J=8Hz), 6.54(1H, d, J=16Hz), 6.68(1H, dd, J=2, 8Hz), 6.98(1H, d, J=2Hz), 7.06(1H, d, J=16Hz), 7.37-7.45(4H, m), 7.49-7.54(2H, m), 7.72(1H, d, J=16Hz).

Mass(ESI) : m/z 586 (M-1).

m.p. 210-212°C.

Example 24

In the same manner as in Example 1, (E)-3-(1-(4-benzyloxy-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide was obtained as colorless crystals (83 mg) from (E)-3-(1-(4-benzyloxy-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-2-propenic acid (90 mg) and (4-methylbenzene)sulfonamide (55 mg).

¹H-NMR(CDCl₃) : 2.32(3H, s), 2.42(3H, s), 5.03(2H, s), 5.10(2H, s), 6.29(1H, d, J=8Hz), 6.51(1H, d, J=16Hz), 6.75(1H, dd, J=2, 8Hz), 7.06(1H, d, J=2Hz), 7.29-7.44(8H, m), 7.95(2H, d, J=8Hz).

Mass (ESI) : m/z 568 (M-1).

5 m.p. 226–228°C.

Example 25

In the same manner as in Example 1, (E)-3-(1-(4-benzyloxy-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide was obtained as colorless
10 crystals (73 mg) from (E)-3-(1-(4-benzyloxy-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-2-propenic acid (90 mg) and (E)-(2-phenylethene)sulfonamide (59 mg).

¹H-NMR(CDCl₃) : 2.34(3H, s), 5.02(2H, s), 5.14(2H, s), 6.34(1H, d, J=8Hz), 6.56(1H, d, J=16Hz), 6.77(1H, dd, J=2, 8Hz), 7.02-7.10(2H, m), 7.31-7.55(11H, m), 7.73(1H, d, J=16Hz).

Mass (ESI) : m/z 580 (M-1) .

m.p. 225–227°C.

Example 26

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-(methylthio)benzyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide was obtained as colorless crystals (83 mg) from (E)-3-(4-chloro-1-(2-chloro-4-(methylthio)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (90 mg) and (4-methylbenzene)sulfonamide (65 mg).

25 $^1\text{H-NMR}(\text{CDCl}_3)$: 2.32 (3H, s), 2.42 (3H, s), 2.47 (3H, s), 5.11 (2H, s), 6.26 (1H, d, $J=8\text{Hz}$), 6.52 (1H, d, $J=16\text{Hz}$), 7.00 (1H, dd, $J=2, 8\text{Hz}$), 7.26-7.36 (4H, m), 7.94 (2H, d, $J=8\text{Hz}$).

Mass (ESI) : m/z 508 (M-1) .

m.p. 228-230°C.

30 Example 27

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-(methylthio)benzyl)-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide was obtained as colorless crystals (97 mg) from (E)-3-(4-chloro-1-(2-chloro-4-(methylthio)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (90 mg) and (E)-(2-phenylethene)sulfonamide (69 mg).

¹H-NMR(CDCl₃) : 2.34(3H, s), 2.46(3H, s), 5.15(2H, s), 6.31(1H, d, J=8Hz), 6.57(1H, d, J=16Hz), 7.00(1H, d, J=2Hz), 7.05(1H, d, J=16Hz), 7.29(1H, d, J=2Hz), 7.35-7.45(4H, m), 7.49-7.55(2H, m), 7.72(1H, d, J=16Hz).

chloro-4-(phenoxyethyl)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide (219 mg) was obtained as a white powder from (E)-3-(4-chloro-1-(2-chloro-4-(phenoxyethyl)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (189 mg) and (E)-
 5 (2-phenylethene)sulfonamide (128 mg).

¹H-NMR(CDCl₃) : 2.30(3H, s), 5.07(2H, s), 5.39(2H, s), 6.50(1H, d, J=8Hz), 6.70(1H, d, J=16Hz), 6.88-7.02(3H, m), 7.22(1H, d, J=16Hz), 7.26-7.48(7H, m), 7.56(1H, d, J=16Hz), 7.62(1H, d, J=2Hz), 7.68-7.80(2H, m), 12.08(1H, br s).

10 Mass(ESI) : m/e 580(M-H)-.

m.p. 202-203°C.

Example 32

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-nitrobenzyl)-2-methylimidazol-5-yl)-N-(4-methylbenzene)sulfonyl)-2-propenamide (63 mg) was obtained as
 15 pale-yellow crystals from (E)-3-(4-chloro-1-(2-chloro-4-nitrobenzyl)-2-methylimidazol-5-yl)-2-propenic acid (105 mg) and (4-methylbenzene)sulfonamide (76 mg).

¹H-NMR(CDCl₃-CD₃OD) : 2.32(3H, s), 2.41(3H, s), 5.24(2H, s),
 20 6.55(1H, d, J=8Hz), 6.68(1H, d, J=15Hz), 7.22(1H, d, J=15Hz), 7.30(2H, d, J=8Hz), 7.90(2H, d, J=8Hz), 8.03(1H, dd, J=8, 2Hz), 8.33(1H, d, J=2Hz).

Mass(ESI) : m/z 507(M-H)-.

m.p. 241-243°C.

25 Example 33

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-nitrobenzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide (78 mg) was obtained as
 pale-yellow crystals from (E)-3-(4-chloro-1-(2-chloro-4-nitrobenzyl)-2-methylimidazol-5-yl)-2-propenic acid (105 mg) and
 30 (E)-(2-phenylethene)sulfonamide (81 mg).

¹H-NMR(CDCl₃-CD₃OD) : 2.34(3H, s), 5.29(2H, s), 6.59(1H, d, J=8Hz),
 6.73(1H, d, J=15Hz), 7.06(1H, d, J=15Hz), 7.30(1H, t, J=8Hz),
 7.37-7.45(3H, m), 7.50-7.52(2H, m), 7.68(1H, d, J=15Hz), 8.05(1H,
 35 dd, J=8, 2Hz), 8.34(1H, d, J=2Hz).

Mass(ESI) : m/z 519(M-H)-.

m.p. 199-201°C.

Example 34

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-
 40 chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-N-

((4-methylbenzene)sulfonyl)-2-propenamide was obtained as thin yellow crystals (81 mg) from (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (150 mg) and (4-methylbenzene)sulfonamide (93 mg).

5 $^1\text{H-NMR}(\text{CDCl}_3)$: 2.33(3H, s), 2.39(3H, s), 5.15(2H, s), 6.35(1H, d, $J=8\text{Hz}$), 6.54(1H, d, $J=16\text{Hz}$), 6.97(1H, d, $J=16\text{Hz}$), 7.08(1H, d, $J=16\text{Hz}$), 7.21-7.41(7H, m), 7.50(2H, d, $J=8\text{Hz}$), 7.55(1H, d, $J=2\text{Hz}$), 7.92(1H, d, $J=8\text{Hz}$).

Mass(ESI) : m/z 564 (M-1).

10 m.p. 237-239°C.

Example 35

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenyl)sulfonyl)-2-propenamide was obtained as
15 colorless crystals (86 mg) from (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (150 mg) and (E)-(2-phenylethene)sulfonamide (100 mg).

$^1\text{H-NMR}(\text{CDCl}_3)$: 2.36(3H, s), 5.20(2H, s), 6.40(1H, d, $J=8\text{Hz}$), 6.58(1H, d, $J=16\text{Hz}$), 6.96(1H, d, $J=16\text{Hz}$), 7.04(1H, d, $J=16\text{Hz}$),
20 7.08(1H, d, $J=16\text{Hz}$), 7.26-7.54(12H, m), 7.58(1H, d, $J=2\text{Hz}$), 7.70(1H, d, $J=16\text{Hz}$).

Mass(ESI) : m/z 576 (M-1).

m.p. 230-232°C.

Example 36

25 In the same manner as in Example 1, (E)-3-(1-(1-bromo-2-naphthyl)-4-chloro-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide (182 mg) was obtained as colorless crystals from (E)-3-(1-(1-bromo-2-naphthyl)-4-chloro-2-methylimidazol-5-yl)-2-propenic acid (175 mg) and (4-methylbenzene)sulfonamide (111 mg).
30

$^1\text{H-NMR}(\text{CDCl}_3)$: 2.30(3H, s), 2.38(3H, s), 5.33(2H, s), 6.42(1H, d, $J=8\text{Hz}$), 6.52(1H, d, $J=15\text{Hz}$), 7.23-7.26(2H, m), 7.37(1H, d, $J=15\text{Hz}$), 7.57(1H, t, $J=8\text{Hz}$), 7.65(1H, d, $J=8\text{Hz}$), 7.70(1H, d, $J=8\text{Hz}$), 7.80(1H, d, $J=8\text{Hz}$), 7.88(2H, d, $J=8\text{Hz}$), 8.31(1H, d, $J=8\text{Hz}$),
35 8.69(1H, br s).

Mass(ESI) : m/z 558 (M-H)-.

m.p. 260-262°C.

Example 37

In the same manner as in Example 1, (E)-3-(1-(1-bromo-2-naphthyl)-4-chloro-2-methylimidazol-5-yl)-N-((E)-2-
40

phenylethenyl)sulfonyl)-2-propenamide (188 mg) was obtained as colorless crystals from (E)-3-(1-(1-bromo-2-naphthyl)-4-chloro-2-methylimidazol-5-yl)-2-propenic acid (175 mg) and (E)-(2-phenylethene)sulfonamide (119 mg).

¹H-NMR(DMSO-d₆) : 2.33(3H, s), 5.59(2H, s), 6.56(1H, d, J=8Hz), 6.70(1H, d, J=15Hz), 7.27(1H, d, J=15Hz), 7.37-7.48(4H, m), 7.53(1H, d, J=15Hz), 7.64(1H, t, J=8Hz), 7.69-7.75(3H, m), 7.94(2H, t, J=8Hz), 8.26(1H, d, J=8Hz).

Mass (ESI) : m/z 570 (M-H) -.

10 m.p. 264–265°C.

Example 38

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide (135 mg) was obtained as colorless
15 crystals from (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (150 mg) and 1-pentanesulfonamide (86 mg).

m.p. 175-176°C

¹H-NMR(CDCl₃) : 0.89 (3H, t, J=6Hz), 0.93 (3H, t, J=6Hz), 1.25-
20 1.48 (8H), 1.70-1.88 (4H), 2.36 (3H, s), 3.45 (2H, t, J=6Hz), 3.92 (2H,
t, J=6Hz), 5.15 (2H, s), 6.35 (1H, d, J=8Hz), 6.52 (1H, d, J=16Hz),
6.71 (dd, J=8, 2Hz), 6.99 (1H, d, J=2Hz), 7.44 (1H, d, J=16Hz),
8.03 (1H, br. s).

MS (ESI) : m/z 529 (M-1) .

25 Example 39

(E)-3-(4-Chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (150 mg) was dissolved in N,N-dimethylformamide (1.5 ml) and carbonyldiimidazole was added. The mixture was stirred at room temperature for 3 hr. To the
30 reaction mixture was added (E)-1-penten-1-ylsulfonamide sodium salt (97 mg), and the mixture was stirred at room temperature for 3 hr and left standing for one day. The reaction mixture was diluted with water (1.5 ml) and adjusted to pH 4 with 1N hydrochloric acid under ice-cooling. The precipitated powder was
35 collected by filtration and washed with water. The resulting white powder was suspended in ethanol (0.75 ml) and heated. The mixture was stirred at room temperature for 30 min. The precipitate was collected by filtration, washed with ethanol and dissolved in N,N-dimethylformamide (0.75 ml) at 80°C. Water (0.25
40 ml) was added at the same temperature and the mixture was stirred

5 propenic acid (150 mg) and (E)-1-penten-1-ylsulfonamide (81 mg).

¹H-NMR(CDCl₃) : 0.92(3H, t, J=7Hz), 1.43-1.57(2H, m), 2.14-2.30(2H, m), 2.37(3H, s), 5.21(2H, s), 6.40(1H, d, J=8Hz), 6.48(1H, d, J=16Hz), 6.57(1H, d, J=16Hz), 6.95-7.15(3H, m), 7.26-7.55(7H, m), 7.60(1H, d, J=1Hz).

10 MS(ESI) : m/z 542(M-1).

m.p. 226–228°C.

Example 43

In the same manner as in Example 1, (E)-N-(1-butanesulfonyl)-3-(4-chloro-1-(2-chloro-4-((E)-2-

15 phenylethenyl)benzyl)-2-methylimidazol-5-yl)-2-propenamide (148 mg) was obtained as colorless crystals from (E)-3-(4-chloro-1-(2-chloro-4-((E)-2-phenylethenyl)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (150 mg) and 1-butanefulfonamide (75 mg).

m.p. 213–214°C

¹H-NMR(CDCl₃) : 0.92(3H, t, J=6Hz), 1.44(2H, m), 1.80(2H, m), 2.48(3H, s), 3.44(2H, t, J=6Hz), 5.22(2H, s), 6.42(1H, d, J=8Hz), 6.59(1H, d, J=16Hz), 7.00(1H, d, J=16Hz), 7.11(1H, d, J=16Hz), 7.25-7.55(7H), 7.60(1H, d, J=2Hz), 8.40(1H, br. s).

MS (ESI) : m/z 531 (M-1).

25 Example 44

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide was obtained as colorless crystals (100 mg) from (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)-

30 benzyl)-2-methylimidazol-5-yl)-2-propenic acid (135 mg) and 1-pentanesulfonamide (74 mg).

¹H-NMR(CDCl₃) : 0.89(3H, t, J=7Hz), 1.25-1.47(4H, m), 1.75-1.90(2H, m), 2.38(3H, s), 3.40-3.47(2H, m), 5.23(2H, s), 6.42(1H, d, J=8Hz), 6.55(1H, d, J=16Hz), 7.31-7.40(3H, m), 7.42(1H, d, J=16Hz), 7.48-7.55(2H, m), 7.63(1H, d, J=1Hz), 7.87(1H, s).

35 7.55(2H, m), 7.63(1H, d, J=1Hz), 7.87(1H, s).

MS (ESI) : m/z 542 (M-1).

m.p. 207–209°C.

Example 45

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-
40 chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-((E)-1-

penten-1-ylsulfonyl)-2-propenamide was obtained as colorless crystals (84 mg) from (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (125 mg) and (E)-1-penten-1-ylsulfonamide (68 mg).

5 ¹H-NMR(CDCl₃) : 0.93(3H, t, J=7Hz), 1.45-1.57(2H, m), 2.20-2.30(2H, m), 2.36(3H, s), 5.22(2H, s), 6.40(1H, d, J=8Hz), 6.48(1H, d, J=16Hz), 6.57(1H, d, J=16Hz), 6.98-7.10(1H, m), 7.30-7.43(4H, m), 7.48-7.55(2H, m), 7.63(1H, d, J=1Hz), 7.87(1H, s).

MS(ESI) : m/z 540(M-1).

10 m.p. 207-210°C.

Example 46

In the same manner as in Example 1, (E)-N-(1-butanesulfonyl)-3-(4-chloro-1-(2-chloro-4-(2-phenylethynyl)benzyl)-2-methylimidazol-5-yl)-2-propenamide (79 mg) was obtained
15 as colorless crystals from (E)-3-(4-chloro-1-(2-chloro-4-(2-phenylethynyl)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (87 mg) and 1-butanesulfonamide (44 mg).

m.p. 217-218°C

¹H-NMR(CDCl₃) : 0.94(3H, t, J=6Hz), 1.45(2H, m), 1.80(2H, m),
20 2.47(3H, s), 3.44(2H, t, J=6Hz), 5.23(2H, s), 6.42(1H, d, J=8Hz), 6.56(1H, d, J=16Hz), 7.30-7.55(7H), 7.62(1H, d, J=2Hz), 8.14(1H, br. s).

MS(ESI) : m/z 529(M-1).

Example 47

25 In the same manner as in Example 1, (E)-3-(4-chloro-1-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethenylsulfonyl)-2-propenamide was obtained as pale-yellow crystals (60 mg) from (E)-3-(4-chloro-1-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-2-methylimidazol-5-yl)-2-
30 propenic acid (120 mg) and (E)-(2-phenylethene)sulfonamide (87 mg).

¹H-NMR(DMSO-d₆) : 2.26(3H, s), 5.65(2H, s), 6.66(1H, d, J=16Hz), 7.27(1H, d, J=16Hz), 7.38-7.48(4H, m), 7.57(1H, d, J=16Hz), 7.70-7.78(2H, m), 8.56(1H, d, J=1Hz), 8.85(1H, s).

MS(ESI) : m/z 545(M+1).

35 m.p. 249-252°C.

Example 48

In the same manner as in Example 1, (E)-3-(4-chloro-1-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-2-methylimidazol-5-yl)-N-((4-methylbenzene)sulfonyl)-2-propenamide was obtained as
40 pale-yellow crystals (38 mg) from (E)-3-(4-chloro-1-((3-chloro-5-

(trifluoromethyl)pyridin-2-yl)methyl)-2-methylimidazol-5-yl)-2-propenic acid (100 mg) and (4-methylbenzene)sulfonamide (68 mg).
¹H-NMR(CDCl₃) : 2.34(3H, s), 2.42(3H, s), 5.33(2H, s), 5.62(1H, d, J=16Hz), 7.26-7.36(3H, m), 7.94(2H, d, J=8Hz), 8.60(2H, s).

5 MS(ESI) : m/z 533(M+1).

m.p. 239-241°C.

Example 49

In the same manner as in Example 1, (E)-3-(1-(4-(tert-butoxycarbonylamino)-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide was obtained as colorless crystals (64 mg) from (E)-3-(1-(4-(tert-butoxycarbonylamino)-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-2-propenic acid (150 mg) and 1-pentanesulfonamide (80 mg).

¹H-NMR(CDCl₃) : 0.89(3H, t, J=7Hz), 1.28-1.46(4H, m), 1.51(9H, s),
 15 1.75-1.89(2H, m), 2.36(3H, s), 3.40-3.48(2H, m), 5.16(2H, s), 6.35(1H, d, J=8Hz), 6.50(1H, d, J=16Hz), 6.55(1H, s), 7.03(1H, dd, J=1, 8Hz), 7.43(1H, d, J=16Hz).

MS(ESI) : m/z 557(M-1).

m.p. 202-204°C.

20 Example 50

In the same manner as in Example 1, (E)-3-(1-(4-(tert-butoxycarbonylamino)-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-((E)-1-penten-1-ylsulfonyl)-2-propenamide was obtained as colorless crystals (59 mg) from (E)-3-(1-(4-(tert-butoxycarbonylamino)-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-2-propenic acid (130 mg) and (E)-1-penten-1-ylsulfonamide (68 mg).

¹H-NMR(DMSO-d₆) : 0.84(3H, t, J=7Hz), 1.35-1.49(2H, m), 1.46(9H, s),
 2.15-2.25(2H, m), 2.31(3H, s), 5.30(2H, s), 6.47(1H, d, J=8Hz),
 6.65(1H, d, J=16Hz), 6.67(1H, d, J=16Hz), 6.75-6.86(1H, m),
 30 7.24(1H, d, J=16Hz), 7.29(1H, dd, J=1, 8Hz), 7.71(1H, s).

MS(ESI) : m/z 555(M-1).

m.p. 209-210°C.

Example 51

In the same manner as in Example 1, (E)-3-(1-(4-(tert-butoxycarbonylamino)-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-N-(((E)-2-phenylethenyl)sulfonyl)-2-propenamide was obtained as a pale-yellow powder (81 mg) from (E)-3-(1-(4-(tert-butoxycarbonylamino)-2-chlorobenzyl)-4-chloro-2-methylimidazol-5-yl)-2-propenic acid (200 mg) and (E)-(2-phenylethene)sulfonamide
 40 (129 mg).

[illegible]

m.p. 197–200°C.

In the same manner as in Example 1, (E)-3-(1-(4-bromo-2-chlorobenzyl)-2,4-dimethylimidazol-5-yl)-N-((E)-2-phenylethenesulfonyl)-2-propenamide (150 mg) was obtained as a colorless powder from (E)-3-(1-(4-bromo-2-chlorobenzyl)-2,4-dimethylimidazol-5-yl)-2-propenic acid (140 mg) and (E)-2-phenylethenesulfonamide (104 mg).

15 Mass (ESI) : m/z 534 (M-H)⁻

In the same manner as in Example 1, (E)-3-(4-bromo-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethanesulfonyl)-2-propenamide (218 mg) was obtained as colorless crystals from (E)-3-(4-bromo-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (200 mg) and (E)-2-phenylethanesulfonamide (124 mg).

Mass (ESI) : m/z 606 (M-H)⁻

In the same manner as in Example 1, (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-4-ethyl-2-methylimidazol-5-yl)-N-((E)-2-phenylethanesulfonyl)-2-propenamide (102 mg) was obtained as a colorless powder from (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-4-ethyl-2-methylimidazol-5-yl)-2-propenic acid (150 mg) and (E)-2-phenylethanesulfonamide (105 mg).

84

J=8Hz), 6.67 (1H, dd, J=8, 2Hz), 6.96 (1H, d, J=2Hz), 7.06 (1H, d, J=15Hz), 7.36-7.44 (3H, m), 7.46-7.59 (3H, m), 7.68 (1H, d, J=15Hz)
Mass (ESI) : m/z 554 (M-H)⁻

Example 67

5 In the same manner as in Example 1, (E)-2-benzyl-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-N-((E)-2-phenylethanesulfonyl)-2-propenamide (138 mg) was obtained as colorless crystals from (E)-2-benzyl-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-propenic acid (200 mg)
10 and (E)-2-phenylethanesulfonamide (121 mg).

¹H-NMR(CDCl₃) : 0.93 (3H, t, J=7Hz), 1.32-1.47 (4H, m), 1.72-1.82 (2H, m), 2.35 (3H, s), 3.90 (2H, t, J=7Hz), 3.96 (2H, s), 5.15 (2H, s), 6.30 (1H, d, J=8Hz), 6.67 (1H, dd, J=8, 2Hz), 6.92-6.98 (2H, m), 7.12 (2H, d, J=8Hz), 7.20-7.32 (5H, m), 7.35-7.45 (5H, m), 7.58 (1H, d, J=8Hz)

Mass (ESI) : m/z 616 (M-H)⁻

m.p. 171-172°C

Example 68

In the same manner as in Example 1, (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-(1-pentyl)-N-((E)-2-phenylethanesulfonyl)-2-propenamide (123 mg) was obtained as colorless crystals from (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-(1-pentyl)-2-propenic acid (200 mg) and (E)-2-phenylethanesulfonamide (127 mg).

25 $^1\text{H-NMR}(\text{CDCl}_3)$: 0.88(3H, t, $J=7\text{Hz}$), 0.92(3H, t, $J=7\text{Hz}$), 1.25-1.55(10H, m), 1.70-1.80(2H, m), 2.37(3H, s), 2.48(2H, t, $J=7\text{Hz}$), 3.89(2H, t, $J=7\text{Hz}$), 5.12(2H, s), 6.32(1H, d, $J=8\text{Hz}$), 6.67(1H, dd, $J=8, 2\text{Hz}$), 6.95-6.97(2H, m), 7.12(1H, d, $J=15\text{Hz}$), 7.27(1H, d, $J=9\text{Hz}$), 7.37-7.47(3H, m), 7.50-7.53(2H, m), 7.72(1H, d, $J=15\text{Hz}$)

30 Mass (ESI) : m/z 596 (M-H)⁻

m.p. 168-169°C

Example 69

In the same manner as in Example 1, (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-((3-pyridyl)methyl)-N-
35 ((E)-2-phenylethanesulfonyl)-2-propenamide (139 mg) was obtained as colorless crystals from (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-(3-pyridyl)methyl-2-propenic acid (230 mg) and (E)-2-phenylethanesulfonamide (139 mg).

¹H-NMR(CDCl₃) : 0.94(3H, t, J=7Hz), 1.32-1.48(4H, m), 1.72-1.82(2H, m), 2.38(3H, s), 3.86(2H, t, J=7Hz), 3.97(2H, s), 5.00(2H, s),

6.37 (1H, d, J=8Hz), 6.61 (1H, d, J=8, 2Hz), 6.92 (1H, d, J=2Hz),
6.95 (1H, s), 6.98 (1H, d, J=15Hz), 7.18-7.27 (2H, m), 7.32-7.45 (5H,
m), 7.56-7.63 (2H, m), 8.09 (1H, s), 8.48 (1H, d, J=5Hz)

Mass (ESI) : m/z 617 (M-H)⁻

5 m.p. 156-158°C

Example 70

In the same manner as in Example 1, (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-methyl-N-((E)-2-phenylethanesulfonyl)-2-propenamide (183 mg) was obtained as
10 colorless crystals from (E)-3-(1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-methyl-2-propenic acid (200 mg) and (E)-2-phenylethanesulfonamide (146 mg).

¹H-NMR (CDCl₃) : 0.92 (3H, t, J=7Hz), 1.30-1.47 (4H, m), 1.71-1.80 (2H, m), 2.12 (3H, s), 2.36 (3H, s), 3.89 (2H, t, J=7Hz), 5.13 (2H, s),
15 6.29 (1H, d, J=8Hz), 6.66 (1H, dd, J=8, 2Hz), 7.08-7.15 (2H, m), 7.33 (1H, s), 7.36-7.47 (3H, m), 7.49-7.53 (2H, m), 7.70 (1H, d, J=15Hz)

Mass (ESI) : m/z 540 (M-H)⁻

m.p. 143-145°C

20 Example 71

In the same manner as in Example 1, (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-methyl-N-((E)-2-phenylethanesulfonyl)-2-propenamide (90 mg) was obtained as
25 colorless crystals from (E)-3-(4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methylimidazol-5-yl)-2-methyl-2-propenic acid (120 mg) and (E)-2-phenylethanesulfonamide (80 mg).

¹H-NMR (CDCl₃) : 0.93 (3H, t, J=7Hz), 1.32-1.48 (4H, m), 1.72-1.82 (2H, m), 1.99 (3H, s), 2.31 (3H, s), 3.91 (2H, t, J=7Hz), 5.00 (2H, s),
30 6.40 (1H, d, J=2Hz), 6.70 (1H, dd, J=8, 2Hz), 6.92-6.94 (2H, m), 7.11 (1H, d, J=15Hz), 7.38-7.45 (3H, m), 7.52-7.55 (2H, m), 7.73 (1H, d, J=15Hz), 8.32 (1H, br s)

Mass (ESI) : m/z 574 (M-H)⁻

m.p. 156-157°C

Example 72

35 In the same manner as in Example 1, 4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-5-((E)-2-phenylethanesulfonyl-carbamoyl)-1H-imidazole (108 mg) was obtained as colorless crystals from 4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-1H-imidazole-5-carboxylic acid (200 mg) and (E)-2-phenylethanesulfonamide (148 mg).
40

$^1\text{H-NMR}(\text{CDCl}_3)$: 0.91(3H, t, $J=7\text{Hz}$), 1.28-1.37(4H, m), 1.60-1.70(2H, m), 2.02(3H, s), 3.62(2H, t, $J=7\text{Hz}$), 5.32(2H, s), 6.32(1H, d, $J=8\text{Hz}$), 6.44(1H, d, $J=8\text{Hz}$), 6.58-6.64(2H, m), 7.05-7.20(6H, m)
 Mass(ESI) : m/z 534(M-H) $^-$

5 m.p. 107-110°C

Example 73

4-Chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-5-hydroxymethyl-2-methyl-1H-imidazole (150 mg) was dissolved in 1,4-dioxane (1.5 ml) and p-toluenesulfonyl isocyanate (99 mg) was added at room temperature. The reaction mixture was stirred at room temperature for 1 hr and concentrated under reduced pressure. To the residue was added ethanol (5 ml) and the precipitated crystals were collected by filtration. The crystals were dissolved in ethyl acetate (2 ml), and hexane (13 ml) was added on an oil bath at 15 70°C. The mixture was allowed to cool and the precipitated crystals were collected by filtration. The crystals were dried by heating under reduced pressure to give (4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-1H-imidazol-5-yl)methyl N-(4-methylbenzenesulfonyl)carbamate (176 mg) as colorless crystals.

20 $^1\text{H-NMR}(\text{CDCl}_3)$: 0.93(3H, t, $J=7\text{Hz}$), 1.32-1.50(4H, m), 1.73-1.83(2H, m), 2.29(3H, s), 2.45(3H, s), 3.93(2H, t, $J=7\text{Hz}$), 4.93(2H, s), 5.02(2H, s), 6.31(1H, d, $J=8\text{Hz}$), 6.68(1H, dd, $J=8, 2\text{Hz}$), 6.94(1H, d, $J=2\text{Hz}$), 7.32(2H, d, $J=8\text{Hz}$), 7.95(2H, d, $J=8\text{Hz}$)

Mass(ESI) : m/z 552(M-H) $^-$

25 m.p. 109-111°C

Example 74

In the same manner as in Example 73, 4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-5-((3-(4-methylbenzenesulfonyl)-ureidomethyl)-2-methyl-1H-imidazole (41 mg) was obtained as 30 colorless crystals from 5-aminomethyl-4-chloro-1-(2-chloro-4-(1-pentyloxy)benzyl)-2-methyl-1H-imidazole (70 mg) and p-toluenesulfonyl isocyanate (43 mg).

$^1\text{H-NMR}(\text{CDCl}_3)$: 0.92(3H, t, $J=7\text{Hz}$), 1.30-1.47(4H, m), 1.70-1.80(2H, m), 2.34(3H, s), 2.43(3H, s), 3.90(2H, t, $J=7\text{Hz}$), 4.24(2H, d, $J=7\text{Hz}$), 5.06(2H, s), 6.25(1H, d, $J=8\text{Hz}$), 6.65-6.68(2H, m), 6.93(1H, d, $J=2\text{Hz}$), 7.28(2H, d, $J=8\text{Hz}$), 7.68(2H, d, $J=8\text{Hz}$)

Mass(ESI) : m/z 551(M-H) $^-$

m.p. 165-166°C

Example 75

40 In the same manner as in Example 73, 4-chloro-1-(2-chloro-4-

nephropathy, diabetic dermatopathy, diabetic neuropathy, diabetic cataract, diabetic retinopathy and the like), insulin resistance syndrome (e.g., insulin receptor abnormality, Rabson-Mendenhall syndrome, leprechaunism, Kobberling-Dunnigan syndrome, Seip syndrome, Lawrence syndrome, Cushing syndrome, acromegaly and the like), polycystic ovary syndrome, hyperlipidemia, atherosclerosis, cardiovascular diseases (e.g., stenocardia, cardiac failure and the like), hyperglycemia (e.g., those characterized by abnormal saccharometabolism such as eating disorders), pancreatitis, osteoporosis, hyperuricemia, hypertension, inflammatory bowel diseases, and skin disorders related to an anomaly of differentiation of epidermic cells; and which, based on the cGMP-PDE (particularly PDE-V) inhibitory action, smooth muscle relaxing action, bronchodilating action, vasodilating action, smooth muscle cell inhibitory action, allergy suppressing action and the like, are used for angina pectoris, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy (e.g., diabetic glomerulosclerosis), tubulointerstitial disorders (e.g., kidney diseases induced by FK506, cyclosporine and the like), renal failure, atherosclerosis, angiostenosis (e.g., after percutaneous arterioplasty), peripheral vascular diseases, cerebral apoplexy, chronic reversible obstructive impairment (e.g., bronchitis, asthma inclusive of chronic asthma and allergic asthma), autoimmune diseases, allergic rhinitis, urticaria, glaucoma, diseases characterized by impaired intestinal motility (e.g., irritable bowel syndrome), impotence (e.g., organic impotence, psychic impotence and the like), nephritis, cancer cachexia or restenosis after PTCA, cachexia (e.g., progressive weight loss due to lipolysis, myolysis, anemia, edema, anorexia and the like in chronic diseases such as cancer, tuberculosis, endocrine diseases and AIDS, and the like. A combination of a compound of formula (I) or pharmaceutically acceptable salts thereof and a retinoid is useful for treating disease states caused by uncontrolled cell proliferation, including cancer, restenosis and atherosclerosis.

This application is based on application Nos. 10-367362 and 11-228838 filed in Japan on December 24, 1998 and August 12, 1999, respectively, the contents of which are incorporated hereinto by reference.